

(TRANSLATION)

PATENT OFFICE
JAPANESE GOVERNMENT

This is to certify that the annexed is a true copy of the following application as filed with this Office.

DATE OF APPLICATION : July 26, 2002

APPLICATION NUMBER : Japanese Patent Application
No. 2002-218958

APPLICANT(S) : Ajinomoto Co., Inc.

Issued :

Commissioner,
Patent Office

(Official Seal)

Certificate No.

[NAME OF DOCUMENT] APPLICATION FOR PATENT

[REFERENCE NO.] PAMA-14175

[FILING DATE] July 26, 2002

[ADDRESS TO] COMMISSIONER, PATENT OFFICE

[INTL' CLASSIFICATION] C12N 9/00

[INVENTOR]

[ADDRESS] c/o Ajinomoto Co., Inc.,
1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi,
Kanagawa Japan

[NAME] Kenzo YOKOZEKI

[INVENTOR]

[ADDRESS] c/o Ajinomoto Co., Inc.,
1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi,
Kanagawa Japan

[NAME] Sonoko SUZUKI

[APPLICANT FOR PATENT]

[CODE NO.] 000000066

[NAME] Ajinomoto Co., Inc.

[AGENT]

[CODE NO.] 100089118

[PATENT ATTORNEY]

[NAME] Hiroaki SAKAI

[INDICATION OF FEE]

[KIND] DEPOSITED

[NUMBER] 036711

[AMOUNT OF FEE] 21000

[LIST OF ATTACHED DOCUMENTS]

[ITEM] SPECIFICATION 1

[ITEM] ABSTRACT 1

[ITEM] RECEIPT IN THE CASE OF AN ORIGINAL
DEPOSIT 2

[DISPLAY OF AIDED] RECEIPT AS FILED BY PROCEDURE

SUPPLEMENTAL DOCUMENT

[NUMBER]

0202890

[Type of Document] Specification

[Title of the Invention] Method for producing tripetides and/or peptides longer than tripeptides

[Scope of Claims for Patent]

5 [Claim 1] A method for producing a peptide that is equal to or longer than a tripeptide, comprising:

 forming the peptide that is equal to or longer than a tripeptide with an enzyme or enzyme-containing substance having the ability to form, from an amine component that is a peptide being equal to or longer than a dipeptide
10 and a carboxy component, a peptide having one more peptide bond than the amine component.

 [Claim 2] The method for producing a peptide that is equal to or longer than a tripeptide according to claim 1, wherein the enzyme or enzyme-containing substance comprises one type or two or more types
15 selected from the group consisting of a culture of a microbe, microbial cells separated from the culture, and a treated microbial cell product of the microbe which have the ability to form, from an amine component that is a peptide being equal to or longer than dipeptide and a carboxy component, a peptide having one more peptide bond than the amine component.

20 [Claim 3] The method for producing a peptide that is equal to or longer than a tripeptide according to claim 1 or 2, wherein the enzyme or enzyme-containing substance is able to use, as substrates, both an amino acid ester and an amino acid amide for the carboxy component.

 [Claim 4] The method for producing a peptide that is equal to or
25 longer than a tripeptide according to any one of claims 1 to 3, wherein the

enzyme or enzyme-containing substance is able to use as a substrate any of a peptide that is equal to or longer than a dipeptide, a C-protected peptide that is equal to or longer than a dipeptide, and a peptide that is equal to or longer than a dipeptide whose C-terminal molecule is an amine instead of an amino acid

5 for the amine component.

[Claim 5] The method for producing a peptide that is equal to or longer than a tripeptide according to claim 2, wherein the microbe is a microbe belonging to the genus *Empedobacter*.

[Claim 6] The method for producing a peptide that is equal to or
10 longer than a tripeptide according to claim 2, wherein the microbe is a microbe that has been transformed so as to be able to express a protein encoded by a DNA (a) or (b):

(a) a DNA having a base sequence consisting of bases numbers 61 to 1908 of a base sequence described in SEQ ID NO: 5 of the Sequence Listing,

15 (b) a DNA that hybridizes with a DNA having a base sequence complementary to the base sequence consisting of bases numbers 61 to 1908 of the base sequence described in SEQ ID NO: 5 of the Sequence Listing under stringent conditions, and encodes a protein that has peptide-forming activity.

20 [Claim 7] The method for producing a peptide that is equal to or longer than a tripeptide according to claim 1, wherein the enzyme is a protein (A) or (B):

(A) a protein having an amino acid sequence described in SEQ ID NO: 6 of the Sequence Listing,

25 (B) a protein having an amino acid sequence including substitution,

deletion, insertion, addition, and/or inversion of one or a plurality of amino acids in the amino acid sequence described in SEQ ID NO: 6 of the Sequence Listing, and having activity to form, from an amine component that is a peptide being equal to or longer than a dipeptide and a carboxy component, a peptide
5 having one more peptide bond than the amine component.

[Claim 8] The method for producing a peptide that is equal to or longer than a tripeptide according to any one of claims 1 to 7, wherein the carboxy component comprises one type or two or more types selected from the group consisting of an L-alanine ester, a glycine ester, and an L-threonine
10 ester.

[Detailed Description of the Invention]

[0001]

[Field of the Invention]

The present invention relates to a method for producing peptides that
15 can produce peptides easily, inexpensively and at high yield without going through a complex synthetic method. More particularly, the present invention relates to a method for producing peptides that are equal to or longer than tripeptides by using an enzyme that catalyzes a peptide-forming reaction from a carboxy component and an amine component.

20 [0002]

[Prior Art]

Peptides are used in the fields of pharmaceuticals, foods and various other fields. For example, since L-alanyl-L-glutamine has higher stability and water-solubility than L-glutamine, it is widely used as a component of fluid
25 infusion and serum-free media.

[0003]

Chemical synthesis methods, which have been known as methods for producing peptides, are not always easy. Known examples of such methods include a method that uses N-benzyloxycarbonylalanine (hereinafter, 5 "Z-alanine") and protected L-glutamine (see Bull. Chem. Soc. Jpn., 34, 739 (1961), Bull. Chem. Soc. Jpn., 35, 1966 (1962)), a method that uses Z-alanine and protected L-glutamic acid- γ -methyl ester (see Bull. Chem. Soc. Jpn., 37, 200 (1964)), a method that uses Z-alanine ester and unprotected glutamic acid (see Japanese Patent Application Laid-open Publication No. H1-96194), a 10 method that involves synthesis of an N-(2-substituted)-propionyl glutamine derivative as an intermediate from a 2-substituted-propionyl halide as a raw material (see Patent Application Laid-open Publication No. H6-234715).

[0004]

However, since all of these methods require the introduction and 15 elimination of protecting groups or the use of an optically active intermediate, they are not considered to be adequately satisfactory in terms of their industrial advantages.

[0005]

On the other hand, widely known examples of typical peptide 20 production methods using enzymes consist of a condensation reaction that uses an N-protected, C-unprotected carboxy component and an N-unprotected, C-protected amine component (hereinafter, "Reaction 1"), and a substitution reaction that uses an N-protected, C-protected carboxy component and an N-unprotected, C-protected amine component (hereinafter, "Reaction 2"). An 25 example of Reaction 1 is a method for producing Z-aspartylphenylalanine

methyl ester from Z-aspartic acid and phenylalanine methyl ester (see Japanese Patent Application Laid-open Publication No. S53-92729), while an example of Reaction 2 is a method for producing acetylphenylalanylleucine amide from acetylphenylalanine ethyl ester and leucine amide (see 5 Biochemical J., 163, 531 (1977)). There have been reported very few research examples of methods that use an N-unprotected, C-protected carboxy component. An example of a substitution reaction that uses an N-unprotected, C-protected carboxy component and an N-unprotected, C-protected amine component (hereinafter, "Reaction 3") is described in 10 International Patent Publication WO 90/01555. For example, a method for producing arginylleucine amide from arginine ethyl ester and leucine amide may be mentioned of. Examples of substitution reactions that use an N-unprotected, C-protected carboxy component and an N-unprotected, C-unprotected amine component (hereinafter, "Reaction 4") are described in 15 European Patent Publications EP 278787A1 and EP 359399B1. For example, a method for producing tyrosylalanine from tyrosine ethyl ester and alanine may be mentioned of.

[0006]

[Problems to be Solved by the Invention]

20 The most inexpensive production method among the aforementioned methods of Reactions 1 to 4 naturally falls within the class of Reaction 4, which involves the fewest protecting groups.

[0007]

However, the example of Reaction 4 of the prior art (European Patent 25 Publication EP 278787A1) had the following major problems: (1) extremely

slow rate of peptide production, (2) low peptide production yield, (3) the peptides that can be produced are limited to those that contain amino acids with comparatively high hydrophobicity, (4) the amount of enzyme added is extremely large, and (5) comparatively expensive carboxypeptidase preparations derived from molds, yeasts or plants are required. In the Reaction 4, there is no method known whatsoever that uses an enzyme derived from bacteria or yeasts other than the genus *Saccharomyces*, and there is no known method for producing alanylglutamine and other peptides that are highly hydrophilic. In consideration of this background, there is a need to develop an industrially inexpensive method for producing these peptides.

[0008]

In addition, the method for producing peptides of the Reaction 4 that uses an enzyme is limited to the formation of dipeptides, and there has been a need to develop a method for simply and easily producing peptides that are equal to or longer than tripeptides so that they can be adequately used industrially.

[0009]

It is an object of the present invention to provide a method that can produce peptides that are equal to or longer than tripeptides to easily, inexpensively and at high yield without going through a complex synthesis method.

[0010]

[Means to Solve the Problems]

As a result of conducting extensive research in consideration of the

aforementioned object, the inventors of the present invention have discovered an enzyme that efficiently forms peptides that are equal to or longer than tripeptides from newly discovered bacteria belonging to the genus *Empedobacter*, and have completed the present invention.

5 [0011]

Namely, the present invention is as described below.

[1] A method for producing a peptide that is equal to or longer than a tripeptide including: forming the peptide that is equal to or longer than a tripeptide with an enzyme or enzyme-containing substance having the ability to
10 form, from an amine component that is a peptide being equal to or longer than a dipeptide and a carboxy component, a peptide having one more peptide bond than the amine component.

[2] The method for producing a peptide that is equal to or longer than a tripeptide according to [1], wherein the enzyme or enzyme-containing
15 substance includes one type or two or more types selected from the group consisting of a culture of a microbe, microbial cells separated from the culture, and a treated microbial cell product of the microbe which have the ability to form, from an amine component that is a peptide being equal to or longer than a dipeptide and a carboxy component, a peptide having one more peptide
20 bond than the amine component.

[3] The method for producing a peptide that is equal to or longer than a tripeptide according to [1] or [2], wherein the enzyme or enzyme-containing substance is able to use as substrates both an amino acid ester and an amino acid amide for the carboxy component.

25 [4] The method for producing a peptide that is equal to or longer than a

tripeptide according to any one of [1] to [3], wherein the enzyme or enzyme-containing substance is able to use as a substrate any of a peptide that is equal to or longer than a dipeptide, a C-protected peptide that is equal to or longer than a dipeptide, and a peptide that is equal to or longer than a dipeptide whose C-terminal molecule is an amine instead of an amino acid for the amine component.

[5] The method for producing a peptide that is equal to or longer than a tripeptide according to [2], wherein the microbe is a microbe belonging to the genus *Empedobacter*.

10 [6] The method for producing a peptide that is equal to or longer than a tripeptide according to [2], wherein the microbe is a microbe that has been transformed so as to be able to express a protein encoded by a DNA (a) or (b):

(a) a DNA having a base sequence consisting of bases numbers 61 to 1908 of a base sequence described in SEQ ID NO: 5 of the Sequence Listing,

15 (b) a DNA that hybridizes with a DNA having a base sequence complementary to the base sequence consisting of bases numbers 61 to 1908 of the base sequence described in SEQ ID NO: 5 of the Sequence Listing under stringent conditions, and encodes a protein that has peptide-forming activity.

20 [7] The method for producing a peptide that is equal to or longer than a tripeptide according to [1], wherein the enzyme is a protein (A) or (B):

(A) a protein having an amino acid sequence described in SEQ ID NO: 6 of the Sequence Listing,

(B) a protein having an amino acid sequence including substitution,
25 deletion, insertion, addition, and/or inversion of one or a plurality of amino

acids in the amino acid sequence described in SEQ ID NO: 6 of the Sequence Listing, and having activity to form, from an amine component that is a peptide being equal to or longer than a dipeptide and a carboxy component, a peptide having one more peptide bond than the amine component.

- 5 [8] The method for producing a peptide that is equal to or longer than a tripeptide according to any one of [1] to [7], wherein the carboxy component comprises one type or two or more types selected from the group consisting of an L-alanine ester, a glycine ester, and an L-threonine ester.

[0012]

10 [Embodiments of the Invention]

The method for producing a peptide that is equal to or longer than a tripeptide according to the present invention is explained in detail in the order of:

1. Method for Producing Peptides that are Equal to or Longer than
15 Tripeptides, and
2. Enzyme Used in the Present Invention.

[0013]

In the present specification, the carboxy component refers to the component that provides a carbonyl site (CO) in the peptide bond (-CONH-),
20 while the amine component refers to the component that provides the amino site (NH) in the peptide bond. In addition, in the present specification, the term "peptide" when used alone refers to a polymer having at least one peptide bond unless otherwise indicated specifically. Further, the term "dipeptide" herein refers to a peptide having one peptide bond. Moreover, the term "a
25 peptide that is equal to or longer than a tripeptide" herein refers to a peptide

having two or more peptide bonds.

[0014]

1. Method for Producing Peptides that are Equal to or Longer than Tripeptides

The method for producing peptides that are equal to or longer than
5 tripeptides according to the present invention (hereinafter also referred to
“peptide production method of the present invention”) is a method in which an
amine component equal to or longer than a dipeptide a carboxy component are
allowed to react with an enzyme or an enzyme-containing substance that has
the ability to form a peptide having one more peptide bond than the amine
10 component, from the amine component and the carboxy component.

[0015]

The action of the enzyme or enzyme-containing substance on the
carboxy component and on the amine component may be accomplished
merely by mixing the enzyme or enzyme-containing substance, the carboxy
15 component and the amine component. More specifically, a method by adding
an enzyme or enzyme-containing substance to a solution containing the
carboxy component and the amine component and by allowing the resultant to
react can be used. Alternatively, in the case of using a microbe that produces
the enzyme, a method by adding the carboxy component and amine
20 component to a microbial culture broth after the enzyme was produced and
accumulated in the microbial cells or in the culture broth can be used. If
necessary, the produced peptide that is equal to or longer than a tripeptide can
then be recovered and purified by conventional methods.

[0016]

25 The term “enzyme-containing substance” means any substance so far

as it contains the enzyme, and examples of specific forms thereof include a microbial culture broth containing the enzyme, microbial cells isolated from the culture, and a product obtained by treating microbial cells (hereinafter, "treated microbial cell product"). A microbial culture broth refers to what is obtained by
5 culturing a microbe, and more specifically, to a mixture of microbial cells, medium used for culturing the microbe and substances produced by the cultured microbe, and so forth. In addition, the microbial cells can be used in the form of washed microbial cells. In addition, the treated microbial cell product includes disrupted, lysed or freeze-dried microbial cells, and the like,
10 and also includes a crude enzyme recovered from treated microbial cells, and a purified enzyme obtained by purification of the crude enzyme, and so forth. A partially purified enzyme obtained by various purification methods may be used as the purified enzyme, or immobilized enzymes may be used that have been immobilized by a covalent bonding method, an adsorption method or an
15 entrapment method. In addition, since some microbes are partially lysed during culturing depending on the microbes used, in such cases, the culture supernatant may also be used as the enzyme-containing substance.

[0017]

In addition, wild strains may be used for the microbes that contain the
20 enzyme, or recombinant strains that express the enzyme obtained by genetic engineering may also be used. The microbes are not limited to intact microbial cells, but rather acetone-treated microbial cells, freeze-dried microbial cells or other treated microbial cells may also be used. Immobilized microbial cells and an immobilized treated microbial cell product obtained by
25 immobilization by covalent bonding, adsorption, entrapment or other methods,

may also be used.

[0018]

Use of a wild strain producing a peptide-forming enzyme having activity to form a peptide, that is equal to or longer than a tripeptide, is rather preferable since the trouble of construction of a recombinant strain by genetic engineering and so forth is eliminated and a peptide is produced more easily. On the other hand, a recombinant strain obtained by genetic engineering that has been transformed to express a peptide-forming enzyme having activity to form a peptide that is equal to or longer than a tripeptide can produce a larger amount of a peptide. So, synthesis of peptides that are equal to or longer than tripeptides can be carried out more rapidly in large amounts. Peptides that are equal to or longer than tripeptides can be produced by mixing amino acid esters and amine component with wild or recombinant microbial culture broth and/or wild or recombinant microbial cells which is cultured in the medium.

[0019]

In addition, in the case of microbial culture broth, cultured microbial cells, washed microbial cells or a treated microbial cell product that has been obtained by disrupting or lysing microbial cells, there are many cases in which an existing enzyme does not participate in peptide formation but decomposes the formed peptides. In this situation, it may be rather preferable in some cases to add a metal protease inhibitor such as ethylenediaminetetraacetic acid (EDTA). The addition amount is within the range of 0.1 millimolar (mM) to 300 mM, and preferably 1 mM to 100 mM.

[0020]

The amount of enzyme or enzyme-containing substance used may be enough if its amount is effective for peptide production (effective amount).

This effective amount can be easily determined through simple and preliminary experimentation by a person with ordinary skill in the art. In the case of using
5 the enzyme, for example, the effective amount is about 0.01 to about 100 units (U), while in the case of using washed microbial cells, the effective amount is about 1 to about 500 grams per liter (g/L).

[0021]

Any carboxy component may be used so far as it can form a peptide by
10 condensation with the amine component that is the other substrate.

Examples of the carboxy component include L-amino acid esters, D-amino acid esters, L-amino acid amides and D-amino acid amides. In addition, examples of the amino acid esters or amino acid amides include amino acid esters or amino acid amides corresponding to not only naturally-occurring
15 amino acids, but also corresponding to non-naturally-occurring amino acids or their derivatives. In addition, examples of the amino acid esters or amino acid amides include not only α -amino acid esters or α -amino acid amides but also β -, γ - and ω - *etc.* amino acid esters or β -, γ - and ω - *etc.* amino acid amides, which have different binding sites of amino groups. Typical examples of the
20 amino acid ester include methyl esters, ethyl esters, n-propyl esters, iso-propyl esters, n-butyl esters, iso-butyl esters, and tert-butyl esters, *etc.* of amino acids.

[0022]

Any peptide may be used for the amine component so far as it can
25 form a peptide by condensation with the carboxy component that is the other

substrate. The minimum unit of the amine component is a dipeptide, while there is no particular upper limit therefor. In addition, there is also no particular restriction on the amino acid sequence of the peptide serving as the amine component. In addition, the peptide used as the amine component
5 may include the one whose side chain was modified, or one that contains amines instead of the amino acids. More specifically, examples of the amine component include peptides being equal to or longer than dipeptides, C-protected peptides being equal to or longer than dipeptides, and peptides being equal to or longer than dipeptides, in which the C-terminal molecule is an
10 amine instead of the amino acid. For example, structure of a tripeptide that is equal to or longer than a dipeptide in which the C-terminal molecule is an amine instead of an amino acid is described as N-terminal amino acid - amino acid - amine.

[0023]

15 Although the concentrations of the carboxy component and amine component serving as starting materials are 1 mM to 10 molar (M), and preferably 0.05 M to 2 M, respectively, there are cases in which it is preferable to add the amine component in an amount equimolar or excess molar with respect to the carboxy component. In addition, when high concentrations of
20 substrates inhibit the reaction, step-wise addition without inhibition can be used during the reaction.

[0024]

The reaction temperature that allows formation of a peptide is 0 to 60°C, and preferably 5 to 40°C. The reaction pH that allows formation of a
25 peptide is 6.5 to 10.5, and preferably 7.0 to 10.0.

[0025]

To produce a peptide being equal to or longer than a tripeptide having a desired amino acid sequence, it is sufficient that amino acid esters serving as the carboxy components be selected step-wisely to make the desired amino acid sequence, with which the amino acids may be successively extended. For example, to produce a tripeptide, L-Ala-L-His-L-Ala, the tripeptide may be synthesized by using alanine methyl ester as the carboxy component and by using a dipeptide, L-His-L-Ala, as the amine component. After formation of the tripeptide, a peptide, Gly-L-Ala-L-His-L-Ala, can be obtained by adding glycine methyl ester as the carboxy component with the above tripeptide as the amine component.

[0026]

2. Enzyme Used in the Present Invention

The aforementioned peptide production method of the present invention employs an enzyme having the ability to form a peptide having one more peptide bond than the amine component from the carboxy component and the peptide as the amine component being equal to or longer than a dipeptide. In the peptide production method of the present invention, there is no particular restriction on the origin or the obtaining method and so forth of the enzyme so far as the enzyme has this activity. Hereinafter, microbes having the enzymes that can be used in the present invention, cultivation of the microbes, purification of the enzymes, and application of genetic engineering techniques will be explained.

[0027]

(2-1) Microbes having Enzyme that can be Used in the Production Method of

the Present Invention

Examples of microbes that form the enzyme of the present invention include bacteria belonging to the genus *Empedobacter* and bacteria belonging to the genus *Sphingobacterium*, and more specifically include *Empedobacter*
5 *brevis* ATCC 14234 strain (FERM P-18545 strain, FERM BP-8113 strain) and *Sphingobacterium* sp. strain FERM BP-8124. *Empedobacter brevis* ATCC 14234 strain (FERM P-18545 strain, FERM BP-8113 strain) and *Sphingobacterium* sp. FERM BP-8124 strain are microbes that the inventors of the present invention isolated through the screening of microbes that produce
10 a peptide from a carboxy component and an amine component in high yield.

[0028]

Empedobacter brevis ATCC 14234 strain (FERM P-18545 strain, FERM BP-8113 strain) was deposited at the International Patent Organism Depositary of the independent administrative corporation, National Institute of
15 Advanced Industrial Science and Technology (Chuo Dai-6, 1-1 Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, Japan) on October 1, 2001 and assigned the deposit number of FERM P-18545. Control of this organism was subsequently transferred to deposition under the provisions of the Budapest Treaty at the International Patent Organism Depositary of the independent
20 administrative corporation, National Institute of Advanced Industrial Science and Technology on July 8, 2002 and was assigned the deposit number of FERM BP-8113 (indication of microbe: *Empedobacter brevis* AJ 13933 strain).

[0029]

Sphingobacterium sp. AJ 110003 strain was deposited at the
25 International Patent Organism Depositary of the independent administrative

corporation, National Institute of Advanced Industrial Science and Technology (Chuo Dai-6, 1-1 Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, Japan) on July 22, 2002, and was assigned the deposit number of FERM BP-8124. The strain FERM BP-8124 is a Gram-negative rod (0.7 to 0.8×1.5 to $2.0 \mu\text{m}$) that
5 forms no spore and is not motile. Its colonies are, round with a completely smooth border, contain low protrusions, have a glossy and light yellow color. The strain FERM BP-8124 grows at 30°C and is catalase positive, oxidase positive and the OF test (glucose) negative. Judging from these results, this strain was identified as a bacterium belonging to the genus *Sphingobacterium*.
10 Moreover, from the properties that nitrate reduction is negative, indole production is negative, acid production from glucose is negative, arginine dihydrolase is negative, urease is positive, esculin hydrolysis is positive, gelatin hydrolysis is negative, β -galactosidase is positive, glucose assimilation is positive, L-arabinose assimilation is negative, D-mannose assimilation is
15 positive, D-mannitol assimilation is negative, N-acetyl-D-glucosamine assimilation is positive, maltose assimilation is positive, potassium gluconate assimilation is negative, n-capric acid is negative, adipic acid assimilation is negative, dl-malic acid assimilation is negative, sodium citrate assimilation is negative, phenyl acetate assimilation is negative and cytochrome oxidase is
20 positive, it was determined to have properties that are similar to those of *Sphingobacterium multivorum* or *Sphingobacterium spiritivorum*. Moreover, although results of analyses on the homology of the base sequence of the 16S rRNA gene indicate the highest degree of homology with *Sphingobacterium multivorum* (98.8%), there was no strain with which the bacterial strain
25 matched completely. Accordingly, this bacterial strain was identified as

Sphingobacterium sp.

[0030]

(2-2) Cultivation of Microbe

To obtain cultured cells of microbes having the enzyme used in the present invention, it suffices that the microbes is cultured and grown in a suitable medium. There is no particular restriction on the medium used for this purpose so far as it allows the microbes to grow. This medium may be an ordinary medium containing ordinary carbon sources, nitrogen sources, phosphorus sources, sulfur sources, inorganic ions, and organic nutrient sources as necessary.

[0031]

For example, any carbon source may be used so far as the microbes can utilize it. Specific examples of the carbon source that can be used include sugars such as glucose, fructose, maltose and amylose, alcohols such as sorbitol, ethanol and glycerol, organic acids such as fumaric acid, citric acid, acetic acid and propionic acid and their salts, carbohydrates such as paraffin as well as mixtures thereof.

[0032]

Examples of nitrogen sources that can be used include ammonium salts of inorganic salts such as ammonium sulfate and ammonium chloride, ammonium salts of organic acids such as ammonium fumarate and ammonium citrate, nitrates such as sodium nitrate and potassium nitrate, organic nitrogen compounds such as peptone, yeast extract, meat extract and corn steep liquor as well as their mixtures.

[0033]

In addition, ordinary nutrient sources used in media, such as inorganic salts, trace metal salts and vitamins, can also be suitably mixed and used.

[0034]

There is no particular restriction on culturing conditions, and cultivation
5 can be carried out, for example, for about 12 to about 48 hours while properly
controlling the pH and temperature with a pH range of 5 to 8 and a temperature
range of 15 to 40°C, respectively, under aerobic conditions.

[0035]

(2-3) Enzyme Purification

10 As previously mentioned, the peptide-forming enzyme used in the
present invention can be purified from bacteria belonging to, for example, the
genus *Empedobacter*. A method for isolating and purifying a peptide-forming
enzyme from *Empedobacter brevis* is explained as an example of purification
of the enzyme.

15 [0036]

First, a microbial cell extract is prepared from microbial cells of
Empedobacter brevis, for example, the strain FERM BP-8113 by disrupting the
cells using a physical method such as ultrasonic disruption or an enzymatic
method using a cell wall-dissolving enzyme and removing the insoluble fraction
20 by centrifugal separation and so forth. The peptide-producing enzyme can
then be purified by fractionating the cell extract containing the enzyme
obtained in the above manner by combining ordinary protein purification
methods such as anion exchange chromatography, cation exchange
chromatography or gel filtration chromatography.

25 [0037]

An example of a carrier for use in anion exchange chromatography is Q-Sepharose HP (manufactured by Amersham). The enzyme is recovered in the non-adsorbed fraction under conditions of pH 8.5 when the cell extract containing the enzyme is applied to a column packed with the carrier.

5 [0038]

An example of a carrier for use in cation exchange chromatography is MonoS HR (manufactured by Amersham). After adsorbing the enzyme onto the column by applying the cell extract containing the enzyme to a column packed with the carrier and then washing the column, the enzyme is eluted
10 with a buffer solution containing a high salt concentration. At that time, the both methods that the salt concentration is step-wisely increased or is gradiently increased are available. For example, in the case of using MonoS HR, the enzyme adsorbed onto the column is eluted at an NaCl concentration of about 0.2 to about 0.5 M.

15 [0039]

The enzyme purified in the manner described above can then be further purified with homogeneity by gel filtration chromatography and so forth. An example of the carrier for use in gel filtration chromatography is Sephadex 200pg (manufactured by Amersham).

20 [0040]

In the aforementioned purification procedure, the fraction containing the enzyme can be verified by assaying the peptide-forming activity of each fraction according to the method indicated in the examples to be described later. The internal amino acid sequence of the enzyme purified in the manner
25 described above is shown in SEQ ID NO: 1 and SEQ ID NO: 2 of the

Sequence Listing.

[0041]

In addition, a preferable mode of the enzyme of the present invention is an enzyme having the property to be able to use both an amino acid ester and
5 an amino acid amide as a substrate for the carboxy component. The words “both an amino acid ester and an amino acid amide can be used as a substrate” means that at least one or more types of amino acid ester and at least one or more types of amino acid amide can be used as a substrate. In addition, another preferable mode of the enzyme of the present invention is an
10 enzyme having the property to be able to use all of a peptide being equal to or longer than a dipeptide, a C-protected peptide being equal to or longer than a dipeptide, and a peptide being equal to or longer than a dipeptide in which the C-terminal molecule is an amine instead of an amino acid as a substrate for the amine component. The words “the ability to use all of a peptide being equal to
15 or longer than a dipeptide, a C-protected peptide being equal to or longer than a dipeptide, and a peptide being equal to or longer than a dipeptide in which the C-terminal molecule is an amine instead of an amino acid” mean that at least one or more types of a peptide being equal to or longer than a dipeptide, at least one or more types of a C-protected peptide being equal to or longer
20 than a dipeptide, and at least one or more types of a peptide being equal to or longer than a dipeptide in which the C-terminal molecule is an amine instead of an amino acid can be used as a substrate. The enzyme of the present invention has a wide range of substrate specificity with respect to the carboxy component or the amino component. The properties are preferable in that a
25 wide range of raw materials can be selected, which in turn is favorable in terms

of cost and production equipment in the case of industrial production.

[0042]

(2-4) Isolation of DNA, Construction of Transformant and Purification of Peptide-forming Enzyme

5 (2-4-1) Isolation of DNA

The inventors of the present invention first succeeded in isolating one type of DNA encoding a peptide-forming enzyme that can be used in the peptide production method of the present invention from *Empedobacter brevis* strain FERM BP-8113. A DNA having a base sequence consisting of bases
10 numbers 61 to 1908 of the base sequence described in SEQ ID NO: 5, which is a DNA of the present invention, was isolated from *Empedobacter brevis* strain FERM BP-8113. Note that the DNA having the base sequence consisting of bases numbers 61 to 1908 is a code sequence (CDS) portion. Furthermore, the various gene recombination techniques indicated below can be carried out
15 in accordance with the descriptions in Molecular Cloning, 2nd edition, Cold Spring Harbor Press (1989) and other publications.

[0043]

A DNA encoding an enzyme that can be used in the present invention can be obtained by polymerase chain reaction (PCR, refer to White, T.J. et al.,
20 Trends Genet., 5, 185 (1989)) or hybridization from a chromosomal DNA or a DNA library of *Empedobacter brevis* or *Sphingobacterium* sp. Primers used in PCR can be designed based on the internal amino acid base sequences determined on the basis of purified peptide-forming enzyme as explained in the previous section (3). In addition, since the base sequences of the
25 peptide-forming enzyme genes (SEQ ID NO: 5) have been identified by the

present invention, primers or hybridization probes can be designed on the basis of these base sequences, and the gene can be isolated using the probes. If primers having sequences corresponding to the 5'-nontranslated region and 3'-nontranslated region, respectively, are used as PCR primers, the full-length encoded region of the enzyme can be amplified. Taking as an example the case of amplifying a region containing both the leader sequence and a mature protein encoding region as described in SEQ ID NO: 5, specific examples of primers include a primer having a base sequence of the region upstream of base number 61 in SEQ ID NO: 5 for the 5'-side primer, and a primer having a sequence complementary to the base sequence of the region downstream of base number 1908 for the 3'-side primer.

[0044]

Primers can be synthesized, for example, according to ordinary methods using the phosphoamidite method (refer to Tetrahedron Letters (1981), 22, 1859) by use of the Model 380B DNA Synthesizer manufactured by Applied Biosystems. The PCR reaction can be carried out, for example, by using the Gene Amp PCR System 9600 (Perkin-Elmer) and the Takara LA PCR In Vitro Cloning Kit (Takara Shuzo) in accordance with the method specified by the supplier such as the manufacturer.

[0045]

A DNA that encodes an enzyme that can be used in the peptide production method of the present invention, regardless of whether the DNA contains a leader sequence or not, includes a DNA that is substantially identical to the DNA consisting of the CDS described in SEQ ID NO: 5 of the Sequence Listing. Namely, a DNA substantially identical to the DNA of the

present invention can be obtained by isolating a DNA consisting of a base sequence complementary to the CDS described in SEQ ID NO: 5 of the Sequence Listing, or a DNA that hybridizes with a probe prepared from the same base sequence under stringent conditions and encodes a protein having peptide-forming activity, from a mutant DNA encoding the enzyme or cells that possess that DNA.

[0046]

The DNA of the present invention, regardless of whether it contains a leader sequence or not, includes a DNA that is substantially identical to the DNA consisting of the CDS described in SEQ ID NO: 11 of the Sequence Listing. Namely, a DNA substantially identical to the DNA of the present invention can be obtained by isolating a DNA consisting of a base sequence complementary to the CDS described in SEQ ID NO: 11 of the Sequence Listing, or a DNA that hybridizes with a probe prepared from the same base sequence under stringent conditions and encodes a protein having peptide-forming activity, from a mutant DNA encoding the enzyme or cells that possess that DNA.

[0047]

A probe can be produced in accordance with conventional methods based on, for example, the base sequence described in SEQ ID NO: 5 of the Sequence Listing. In addition, a method for isolating a target DNA by using a probe to find a DNA that hybridizes with the probe may also be carried out in accordance with conventional methods. For example, a DNA probe can be produced by amplifying a base sequence cloned in a plasmid or phage vector, cleaving the base sequence desired to be used as a probe with a restriction

enzyme and then extracting the desired base sequence. The cleaving site can be adjusted depending on the target DNA.

[0048]

The term "stringent conditions" as used herein refers to conditions
5 under which a so-called specific hybrid is formed but no non-specific hybrid is formed. It is difficult to precisely express this condition in numerical values. For example, mention may be made of a condition under which DNAs having a high homology, for example, 50% or more, preferably 80% or more, more preferably 90% or more, hybridize with each other and DNAs having a lower
10 homology than these do not hybridize with each other, or ordinary conditions for rinse in southern hybridization under which hybridization is performed at 60°C in a salt concentration corresponding to 1×SSC and 0.1% SDS, preferably 0.1×SSC, and 0.1% SDS. Although the genes that hybridize under such conditions include genes in which a stop codon occurs at an intermediate
15 site or which lose activity due to a mutation in the active center, these can be easily removed by assaying the enzyme activity of the expression product using a method to be described later after ligating them to a commercially available expression vector, expressing them in a suitable host.

[0049]

20 An amino acid sequence encoded by the CDS described in SEQ ID NO: 5 of the Sequence Listing is shown in SEQ ID NO: 6 of the Sequence Listing. In addition, an amino acid sequence encoded by the CDS described in SEQ ID NO: 11 of the Sequence Listing is shown in SEQ ID NO: 12 of the Sequence Listing. The protein encoded by the DNA of the present invention
25 is a protein in which the mature protein has peptide-forming activity, and a DNA

that encodes a protein substantially identical to a protein having the amino acid sequence described in SEQ ID NO: 6 or SEQ ID NO: 12 of the Sequence Listing, is also included in the DNA of the present invention unless such an activity is deteriorated.

5 [0050]

Namely, the present invention provides DNAs that encode proteins indicated in (A) and (B):

(A) A protein having an amino acid sequence described in SEQ ID NO: 6 or SEQ ID NO: 12 of the Sequence Listing;

10 (B) A protein having an amino acid sequence including substitution, deletion, insertion, addition or inversion of one or a plurality of amino acids in the amino acid sequence described in SEQ ID NO: 6 or SEQ ID NO: 12 of the Sequence Listing, and having activity to form a peptide. Base sequences are specified from amino acid sequences in accordance with the codes of the universal
15 codons.

[0051]

Here, the term "a plurality of", which may vary depending on the locations in the three-dimensional structure of the protein of and types of the amino acid residues, means 2 to 100, preferably 2 to 50 and more preferably 2
20 to 10.

[0052]

A mutation of an amino acid such as those indicated in the aforementioned (B) is obtained by modifying the base sequence of the gene of the enzyme of the present invention so that amino acids of the enzyme gene in
25 specific sites are substituted, deleted, inserted or added. In addition, modified

DNAs such as those described above can also be obtained by conventionally known mutagenesis treatments. Mutagenesis treatments include, for example, a method in which a DNA that encodes the enzyme is treated *in vitro* with hydroxylamine or the like, as well as a method in which bacteria belonging to the genus *Escherichia* that possess a DNA encoding the enzyme are treated by a mutagen normally used in artificial mutagenesis, such as ultraviolet irradiation, N-methyl-N'-nitro-N-nitrosoguanidine (NTG) or nitrous acid.

[0053]

In addition, the base substitution, deletion, insertion, addition or inversion described above also include naturally-occurring mutations such as differences attributable to a microbe species or strain. By expressing a DNA having such a mutation in suitable cells and examining the enzyme activity of the expression product, a DNA can be obtained that encodes the protein described in SEQ ID NO: 6 of the Sequence Listing or a protein substantially identical thereto.

[0054]

(2-4-2) Construction of Transformants and Production of Peptide-forming Enzymes

A peptide-forming enzyme that can be used in the peptide production method of the present invention can be produced by introducing the DNA explained in the aforementioned section (2-4-1) into a suitable host and expressing within that host.

[0055]

With respect to hosts for expressing a protein encoded by the DNA, examples of the hosts that can be used include various prokaryotic cells

including bacteria belonging to the genus *Escherichia* such as *Escherichia coli*, *Empedobacter*, *Sphingobacterium*, *Flavobacterium* and *Bacillus subtilis*, as well as various eukaryotic cells including *Saccharomyces cerevisiae*, *Pichia stipitis* and *Aspergillus oryzae*.

5 [0056]

A recombinant DNA used to introduce a DNA into a host can be prepared by inserting the DNA to be introduced into a vector corresponding to the type of host in which the DNA is to be expressed, in such a form that the protein encoded by that DNA can be expressed. If a promoter that is
10 originally associated with the gene encoding the peptide-forming enzyme in, e.g., *Empedobacter brevis* is capable of working in the host cells, such a promoter can be used as the promoter for expressing the DNA in the present invention. If necessary, another promoter that is capable of working in the host cells may be connected to the DNA of the present invention, for
15 expressing the DNA under the control of the promoter.

[0057]

Examples of transformation methods for introducing a recombinant DNA into host cells include the method of D.M. Morrison (see Methods in Enzymology, 68, 326 (1979)) or the method in which DNA permeability is
20 increased by treating receptor microbial cells with calcium chloride (see Mandel, H. and Higa, A., J. Mol. Biol., 53, 159 (1970)).

[0058]

In the case of mass production of a protein using recombinant DNA technology, conjugating the protein within a transformant that produces the
25 protein to form an inclusion body of protein is also a preferable mode for

carrying out the present invention. Advantages of this expression and production method include protection of the target protein from digestion by proteases present within the microbial cells, and simple and easy purification of the target protein by disrupting the microbial cells followed by centrifugal separation and so forth.

[0059]

The inclusion body of protein obtained in this manner is solubilized with a protein denaturant and the protein is converted to a properly folded, physiologically active protein through an activity regeneration procedure that consists primarily of removal of the denaturant. There are numerous examples of this, including regeneration of the activity of human interleukin-2 (see Japanese Patent Application Laid-open Publication No. S61-257931).

[0060]

To obtain an active protein from inclusion bodies, a series of procedures including solubilization and activity regeneration are required, and the procedure is more complex than the case of producing the active protein directly. However, in the case of producing a protein that has a detrimental effect on microbial growth in large volumes within microbial cells, that effect can be suppressed by accumulating the proteins in the form of inclusion bodies of protein that are inactive in the microbial cells.

[0061]

Examples of mass production methods for producing a target protein in the form of inclusion bodies include a method in which a target protein is expressed independently under the control of a powerful promoter, and a method in which a target protein is expressed in the form of a fused protein

with a protein that is known to be expressed in a large volume.

[0062]

Hereinafter, the present invention will be explained more specifically taking as an example a method for producing transformed *Escherichia coli* and using that transformed microbe to produce a peptide-forming enzyme. Promoters normally used in the production of heterogeneous proteins in *Escherichia coli* can be used as a promoter for expressing a DNA encoding a peptide-forming enzyme. Examples of such promoters include T7 promoter, lac promoter, trp promoter, trc promoter, tac promoter, lambda phage PR promoter, PL promoter and other powerful promoters. In addition, examples of vectors that can be used include pUC19, pUC18, pBR322, pHSG299, pHSG298, pHSG399, pHSG398, RSF1010, pMW119, pMW118, pMW219, and pMW218. Besides, vectors of phage DNA can also be used. Moreover, expression vectors that contain promoters and are capable of expressing an inserted DNA sequence can be used.

[0063]

To produce peptide-forming enzyme in the form of a fused protein inclusion body, a gene that encodes another protein, and preferably a hydrophilic peptide, is ligated upstream or downstream of the peptide-forming enzyme gene. The gene that encodes another protein in this manner may be any gene that increases the amount of the fused protein accumulated and enhances the solubility of the fused protein after the denaturation and regeneration steps. Examples of candidates for such genes include T7 gene 10, β -galactosidase gene, dehydrofolate reductase gene, γ -interferon gene, interleukin-2 gene and prochymosin gene.

[0064]

When these genes are ligated to the genes that encode peptide-forming enzymes, the genes are ligated so that reading frames of codons are consistent. It is recommended that the genes be ligated at a proper restriction enzyme site or a synthetic DNA having a proper sequence be utilized.

[0065]

Further, to increase a production amount of the peptide-forming enzyme, it is preferable in some cases that a terminator, which is a transcription terminating sequence, be ligated to downstream of the fusion protein gene. The terminator includes, for example, a T7 terminator, an fd phage terminator, a T4 terminator, a tetracycline resistant gene terminator, and an *Escherichia coli* trpA gene terminator.

[0066]

As the vectors for introducing a gene that encodes a peptide-forming enzyme or a fused protein between the peptide-forming enzyme and another protein in *Escherichia coli* are preferred so-called multi-copy type vectors, examples of which include a plasmid having a replicator derived from ColE1, such as a pUC-based plasmid, and a pBR322-based plasmid or derivatives thereof. The "derivatives" as used herein refer to those plasmids that are subjected to modification by substitution, deletion, insertion, addition or inversion of bases. Note that the modification as used herein includes modifications by a mutagenesis treatment with a mutagen or UV irradiation, or modifications by spontaneous mutation.

[0067]

To screen transformants, it is preferable that the vectors have markers such as an ampicillin resistant gene. These plasmids are commercially available expression vectors having potent promoters (a pUC-based vector (manufactured by Takara Shuzo, Co., Ltd.), such as pRROK-based vector
5 (manufactured by Clontech Laboratories, Inc.), pKK233-2 (manufactured by Clontech Laboratories, Inc.) and so forth.

[0068]

A recombinant DNA is obtained by ligating a DNA fragment to a vector DNA. In this case, a promoter, a gene encoding the peptide-forming enzyme
10 or a fused protein consisting of the peptide-forming enzyme and another protein, and depending on the case, a terminator are ligated in that order.

[0069]

When *Escherichia coli* is transformed using the recombinant DNA and the resulting *Escherichia coli* is cultured, a peptide-forming enzyme or a fused
15 protein consisting of the peptide-forming enzyme and another protein is expressed and produced. Although a strain that is normally used in the expression of a heterogeneous gene can be used as a host to be transformed, *Escherichia coli* JM109, for example, is preferable. Methods for transformation and methods for selection from transformants are described in
20 Molecular Cloning, 2nd Edition, Cold Spring Harbor Press (1989) and other publications.

[0070]

In the case of expressing a peptide-forming enzyme in the form of a fusion protein, the peptide-forming enzyme may be cleaved out using a
25 restriction protease that uses a sequence not present in the peptide-forming

enzyme, such as blood coagulation factor Xa or kallikrein, as the recognition sequence.

[0071]

A medium normally used for culturing *Escherichia coli*, such as
5 M9-casamino acid medium or LB medium, may be used as a production medium. In addition, culturing conditions and induction conditions for production are suitably selected according to a variety of markers of the vector, promoter, type of host microbe and so forth.

[0072]

10 The following method can be used to recover the peptide-forming enzyme or fused protein consisting of the peptide-forming enzyme and another protein. If the peptide-forming enzyme or its fused protein was produced as solubilized form within the microbial cells, after recovering the microbial cells, the microbial cells are disrupted or lysed so that they can be used as a crude
15 enzyme liquid. Moreover, the peptide-forming enzyme or its fused protein can be purified prior to use by ordinary techniques such as precipitation, filtration or column chromatography as necessary. In this case, a purification method using an antibody of the peptide-forming enzyme or its fused protein can also be used .

20 [0073]

In the case where protein inclusion bodies are formed, the inclusion bodies are solubilized with a denaturant. They may be solubilized together with the microbial cell protein. However, in consideration of the following purification procedure, the inclusion bodies are preferably taken out and then
25 solubilized. Conventionally known methods may be used to recover the

inclusion bodies from the microbial cells. For example, inclusion bodies can be recovered by disrupting the microbial cells followed by centrifugal separation. Examples of denaturants capable of solubilizing inclusion bodies include guanidine hydrochloride (for example, 6 M, pH 5 to 8) and urea (for
5 example, 8 M).

[0074]

A protein having activity is regenerated by removing these denaturants by dialysis. A Tris-HCl buffer solution or a phosphate buffer solution and so forth may be used as solution used in dialysis, and the concentration may be,
10 for example, 20 mM to 0.5 M, while the pH may be, for example, 5 to 8.

[0075]

The protein concentration during the regeneration step is preferably held to about 500 µg/ml or less. The dialysis temperature is preferably 5°C or lower to inhibit the regenerated peptide-forming enzyme from undergoing
15 self-crosslinking. Moreover, in addition to dialysis, dilution or ultrafiltration may be used to remove the denaturants, and it is expected that the activity can be regenerated regardless of whichever denaturant is used.

[0076]

[Examples]

20 Hereinafter, the present invention will be explained by examples. However, the present invention is not limited to these examples. In addition to confirmation by ninhydrin coloring of thin-film chromatograms (qualitative), quantitative determinations were made by the following high-performance liquid chromatography in order to assay products. Column: Inertsil ODS-2
25 (manufactured by GL Science, Inc.), eluate: aqueous phosphate solution

containing 5.0 mM sodium 1-octanesulfonate (pH 2.1) : methanol = 100 : 15 to 50, flow rate: 1.0 mL/min, detection: 210 nanometers (nm).

[0077]

(Example 1) Cultivation of Microbe

5 A 50 mL medium (pH 6.2) containing 5 grams (g) glucose, 5 g ammonium sulfate, 1 g monopotassium phosphate, 3 g dipotassium phosphate, 0.5 g magnesium sulfate, 10 g yeast extract and 10 g peptone in 1 liter (L) was transferred to a 500 mL Sakaguchi flask and sterilized at 115°C for 15 minutes. This medium was then inoculated with one loopful cells of *Empedobacter*
10 *brevis* strain FERM BP-8113 that had been cultured at 30°C for 16 hours in the same medium, followed by shake culturing at 30°C for 16 hours and 120 strokes/min.

[0078]

(Example 2) Production of Peptide Using Microbial Cells

15 Microbial cells were collected by centrifuging (10,000 rounds per minute (rpm), 15 minutes) the culture broth obtained in Example 1 followed by suspending to a concentration of 100 g/L in 100 mM borate buffer (pH 9.0) containing 10 mM EDTA. After respectively adding 1 mL of this suspension to 1 mL of 100 mM borate buffer (pH 9.0) containing 10 mM EDTA, 200 mM of the
20 following carboxy components and 400 mM of the following amino acids to bring to a final volume of 2 mL, the reaction was carried out at 18°C for 2 hours. The peptides that were formed as a result of this reaction are shown in Table 1.

[0079]

[Table 1]

Carboxy com- ponent	Amine com- ponent	Formed (mM) peptide		Carboxy com- ponent	Amine com- ponent	Formed (mM) peptide	
L-Ala-OMe	L-Leu	L-Ala-L-Leu	38.2	Gly-OMe	L-His	L-Gly-L-His	22.1
	L-Met	L-Ala-L-Met	68.3	L-Ser-OMe	L-Ser	L-Ser-L-Ser	29.0
	L-Phe	L-Ala-L-Phe	62.4	L-Val-OMe	L-Met	L-Val-L-Met	10.5
	L-Ser	L-Ala-L-Ser	51.3	L-Met-OMe	L-Phe	L-Met-L-Phe	28.5
	L-His	L-Ala-L-His	52.1	L-Thr-OMe	L-Leu	L-Thr-L-Leu	23.0
	L-Arg	L-Ala-L-Arg	72.1	L-Ile-OMe	L-Met	L-Ile-L-Met	8.3
	L-Gln	L-Gln	68.0				

(Hydrochloride salts were used for all the carboxy components.)

[0080]

5 (Example 3) Purification of Enzyme

The procedure after centrifugal separation was carried out either on ice or at 4°C. *Empedobacter brevis* strain FERM BP-8113 was cultivated in the same manner in as Example 1, and the microbial cells were collected by centrifugal separation (10,000 rpm, 15 minutes). After washing 16 g of

10 microbial cells with 50 mM Tris-HCl buffer (pH 8.0), they were suspended in 40 milliliters (ml or mL) of the same buffer and subjected to ultrasonic disrupting treatment for 45 minutes at 195 watts. This sonicate was then centrifuged (10,000 rpm, 30 minutes) to remove the cell debris and obtain an ultrasonically

disrupted liquid supernatant. This ultrasonically disrupted liquid supernatant was dialyzed overnight against 50 mM Tris-HCl buffer (pH 8.0) followed by removal of the insoluble fraction by ultracentrifugation (50,000 rpm, 30 minutes) to obtain a soluble fraction in the form of the supernatant liquid. The
5 resulting soluble fraction was applied to a Q-Sepharose HP column (manufactured by Amersham) pre-equilibrated with Tris-HCl buffer (pH 8.0), and the active fraction was collected from the non-adsorbed fraction. This active fraction was dialyzed overnight against 50 mM acetate buffer (pH 4.5) followed by removal of the insoluble fraction by centrifugal separation (10,000
10 rpm, 30 minutes) to obtain a dialyzed fraction in the form of the supernatant liquid. This dialyzed fraction was then applied to a Mono S column (manufactured by Amersham) pre-equilibrated with 50 mM acetate buffer (pH 4.5) to elute enzyme with a linear concentration gradient of the same buffer containing 0 to 1 M NaCl. The fraction that had the lowest level of
15 contaminating protein among the active fractions was applied to a Superdex 200pg column (manufactured by Amersham) pre-equilibrated with 50 mM acetate buffer (pH 4.5) containing 1 M NaCl, and gel filtration was performed by allowing the same buffer (pH 4.5) containing 1 M NaCl to flow through the column to obtain an active fraction solution. As a result of performing these
20 procedures, the peptide-forming enzyme used in the present invention was confirmed to have been purified with homogeneity based on the experimental results of electrophoresis. The enzyme recovery rate in the aforementioned purification process was 12.2% and the degree of purification was 707 folds.

[0081]

25 (Example 4) Measurement of Molecular Weight of Enzyme

(SDS-Gel Electrophoresis)

A 0.3 microgram (μg) equivalent of the purified enzyme fraction obtained by the method of Example 3 was applied to polyacrylamide electrophoresis. 0.3% (w/v) Tris, 1.44% (w/v) glycine and 0.1% (w/v) sodium laurylsulfate were used for the electrophoresis buffer solution, a gel having a concentration gradient of 10 to 20% (Multigel 10 to 20, manufactured by Daiichi Pure Chemicals) was used for the polyacrylamide gel, and Pharmacia molecular weight markers were used for the molecular weight markers. Following completion of electrophoresis, the gel was stained with Coomassie brilliant blue R-250, and a homogeneous band was detected at the location of a molecular weight of about 75 kilodalton (kDa).

[0082]

(Gel filtration)

The purified enzyme fraction obtained by the method of Example 3 was applied to a Superdex 200pg column (manufactured by Amersham) pre-equilibrated with 50 mM acetate buffer (pH 4.5) containing 1 M NaCl, and gel filtration was carried out by allowing the same buffer (pH 4.5) containing 1 M NaCl to flow through the column to measure the molecular weight. Pharmacia molecular weight markers were used as standard proteins having known molecular weights to prepare a calibration curve. As a result, the molecular weight of the enzyme was about 150 kDa.

[0083]

Based on the results of SDS-gel electrophoresis and gel filtration, the enzyme was suggested to be a homodimer having a molecular weight of about 75 kDa.

[0084]

(Example 5) Optimum pH of Enzyme

The effects of pH for L-alanyl-L-glutamine production from L-alanine methyl ester hydrochloride and L-glutamine were examined. Acetate buffer (pH 3.9 to 5.4), MES buffer (pH 5.4 to 6.4), phosphate buffer (pH 6.0 to 7.9), borate buffer (pH 7.8 to 9.3), CAPS buffer (pH 9.3 to 10.7) and K₂HPO₄-NaOH buffer (pH 10.8 to 11.6) were used as buffers. 1 microliter (μl) of the Mono S fraction enzyme obtained in Example 3 (about 180 U/ml) was added to 100 μl of 100 mM each buffer containing 100 mM L-alanine methyl ester, 200 mM L-glutamine and 10 mM EDTA and allowed to react at 18°C for 5 minutes to measure the effects of pH on the reaction. The results based on assigning a value of 100% to the case of using borate buffer (pH 9.3) are shown in Fig. 1. As a result, the optimum enzyme pH was 8 to 9.5.

[0085]

(Example 6) Optimum Temperature of Enzyme

The effects of temperature for L-alanyl-L-glutamine production from L-alanine methyl ester hydrochloride and L-glutamine were examined. 1 μl of the same enzyme fraction used in Example 5 was added to 100 μl of 100 mM borate buffer (pH 9.0) containing 100 mM L-alanine methyl ester, 200 mM L-glutamine and 10 mM EDTA and allowed to react for 5 minutes at each temperature to measure the effects of temperature on the reaction. The results based on assigning a value of 100% to the activity at 34°C are shown in Fig. 2. As a result, the optimum enzyme temperature was 30 to 40°C.

[0086]

(Example 7) Enzyme Inhibitors

The effects of inhibitors on L-alanyl-L-glutamine production were examined using L-alanine methyl ester hydrochloride and L-glutamine as substrates. 2 μ l of the same enzyme fraction used in Example 5 was added to 50 μ l of 100 mM borate buffer (pH 9.0) containing 10 mM each of the enzyme inhibitors shown in Table 2, and allowed to react at 25°C for 5 minutes. Note that, o-phenanthroline, phenylmethanesulfonyl fluoride and p-nitrophenyl-p'-guanidinobenzoate were dissolved in methanol to a concentration of 50 mM before use. The enzyme activity under each condition was indicated as the relative activity in the case of assigning a value of 100 to the production of L-alanyl-L-glutamine in the absence of enzyme inhibitor. Those results are shown in Table 2. As a result, among the serine enzyme inhibitors tested, the enzyme was not inhibited by phenylmethanesulfonyl fluoride, but it was inhibited by p-nitrophenyl-p'-guanidinobenzoate.

[0087]

[Table 2]

Enzyme inhibitor		Relative activity of L-Ala-L-Gln production (%)
None		100
Metal enzyme inhibitor	EDTA	96
	o-Phenanthroline	96
SH enzyme inhibitor	N-Ethyl maleimide	110
	Monoiodoacetate	101
Serine enzyme inhibitor	Phenylmethylsulfonyl fluoride	115
	4-(2-Aminoethyl)benzene sulfonyl fluoride	75
	p-Nitrophenyl-p'-guanidino benzoate	0.1

[0088]

(Example 8) L-Alanyl-L-Glutamine Production from L-Alanine Methyl Ester and L-Glutamine

3 μ l of the same enzyme fraction as used in Example 5 was added to 100 μ l of 100 mM borate buffer (pH 9.0) containing 100 mM L-alanine methyl ester hydrochloride, 200 mM L-glutamine and 10 mM EDTA, and allowed to react at 18°C. As a result, as shown in Fig. 3, 83 mM L-alanyl-L-glutamine (L-Ala-L-Gln) was formed in the case of an enzyme-added lot, and the concentration of by-product L-Ala-L-Ala-L-Gln was 1.3 mM. On the other hand, there was scarcely any production of L-Ala-L-Gln observed in an enzyme-non-added lot, and L-Ala-L-Gln production was only about 0.07 mM

after reaction for 120 minutes.

[0089]

(Example 9) Effects of L-Glutamine Concentration on L-Alanyl-L-Glutamine Production

5 1 μ l of the same enzyme fraction as used in Example 5 was added to 100 μ l of 100 mM borate buffer (pH 9.0) containing 100 mM L-alanine methyl ester hydrochloride, L-glutamine at the concentrations shown in Table 3 and 10 mM EDTA, and allowed to react at 18°C for 2 hours. Those results are shown in Table 3.

10

[Table 3]

L-Alanine methyl ester hydrochloride (mM)	L-Glutamine (mM)	L-Ala-L-Gln (mM)
100	100	68.2
	110	72.1
	120	73.3
	130	75.1
	150	75.5
	200	82.0

[0090]

(Example 10) Substrate Specificity of Enzyme (1)

Ester specificity was examined in the case of using L-amino acid ester
15 as the carboxy component. 2 μ l of the same enzyme fraction as used in Example 5 was added to 100 μ l of 100 mM borate buffer (pH 9.0) containing

the 100 mM carboxy components indicated in Table 4, 200 mM L-glutamine and 10 mM EDTA, and allowed to react at 25°C for 2 hours. The amounts of L-Ala-L-Gln formed in this reaction are shown in Table 4 (HCl represents hydrochloride in Table 4).

5

[Table 4]

Carboxy component	L-Ala-L-Gln formed (mM)
L-Alanine methyl ester·HCl	84.3
L-Alanine ethyl ester·HCl	91.5
L-Alanine isopropyl ester·HCl	78.9
L-Alanine-t-butyl ester·HCl	7.5

[0091]

(Example 11) Substrate Specificity of Enzyme (2)

Peptide production by using L-alanine methyl ester as the carboxy component and various L-amino acids as the amine component was examined. 2 µl of the same enzyme fraction as used in Example 5 was added to 100 µl of 100 mM borate buffer (pH 9.0) containing 100 mM L-alanine methyl ester hydrochloride, the 150 mM L-amino acids shown in Table 5 and 10 mM EDTA, and allowed to react at 25°C for 3 hours. The amounts of each peptide formed in this reaction are shown in Table 5. (The "+" mark indicates that peptides production was confirmed but were unable to be quantified due to the absence of a standard, while "tr" indicates a trace amount.)

[Table 5]

Amine component	Formed peptide (mM)		Amine component	Formed peptide (mM)	
Gly	L-Ala-Gly	13.7	L-Asn	L-Ala-L-Asn	65.5
L-Ala	L-Ala-L-Ala	25.4	L-Gln	L-Ala-L-Gln	79.3
L-Val	L-Ala-L-Val	20.8	L-Tyr	L-Ala-L-Tyr	17.6
L-Leu	L-Ala-L-Leu	45.3	L-CySH	L-Ala-L-CySH	+
L-Ile	L-Ala-L-Ile	33.9	L-Lys	L-Ala-L-Lys	71.8
L-Met	L-Ala-L-Met	83.3	L-Arg	L-Ala-L-Arg	88.0
L-Phe	L-Ala-L-Phe	74.4	L-His	L-Ala-L-His	66.9
L-Trp	L-Ala-L-Trp	53.9	L-Asp	L-Ala-L-Asp	2.1
L-Ser	L-Ala-L-Ser	62.5	L-Glu	L-Ala-L-Glu	42.9
L-Thr	L-Ala-L-Thr	53.9	L-Pro	L-Ala-L-Pro	tr

[0092]

(Example 12) Substrate Specificity of Enzyme (3)

Peptide production by using various types of L-amino acid methyl esters as the carboxy component and L-glutamine as the amine component was examined. 2 μ l of the same enzyme fraction as used in Example 5 was added to 100 μ l of 100 mM borate buffer (pH 9.0) containing 100 mM L-amino acid methyl ester hydrochlorides (AA-OMe·HCl) shown in Table 6, 150 mM L-glutamine and 10 mM EDTA, and allowed to react at 25°C for 3 hours. The amounts of each of the peptides formed in this reaction are shown in Table 6. (The “+” mark indicates that peptides production was confirmed but were unable to be quantified due to the absence of a standard, while “tr” indicates a

trace amount.) Furthermore, Tween-80 was added to the reaction system to a final concentration of 0.1% in the case of using L-Trp-OMe and L-Tyr-OMe.

[Table 6]

Carboxy component	Formed peptide (mM)		Carboxy component	Formed peptide (mM)	
Gly-OMe	Gly-L-Gln	54.7	L-Tyr-OMe	L-Tyr-L-Gln	3.4
L-Ala-OMe	L-Ala-L-Gln	74.6	CySH-OMe	L-CySH-L-Gln	+
L-Val-OMe	L-Val-L-Gln	15.4	L-Lys-OMe	L-Lys-L-Gln	+
L-Leu-OMe	L-Leu-L-Gln	+	L-Arg-OMe	L-Arg-L-Gln	7.1
L-Ile-OMe	L-Ile-L-Gln	8.4	L-His-OMe	L-His-L-Gln	+
L-Met-OMe	L-Met-L-Gln	12.0	L-Asp- α -OMe	α -L-Asp-L-Gln	tr
L-Phe-OMe	L-Phe-L-Gln	0.9	L-Asp- β -OMe	β -L-Asp-L-Gln	tr
L-Trp-OMe	L-Trp-L-Gln	+	L-Glu- α -OMe	α -L-Glu-L-Gln	+
L-Ser-OMe	L-Ser-L-Gln	24.0	L-Glu- γ -OMe	γ -L-Glu-L-Gln	+
L-Thr-OMe	L-Thr-L-Gln	81.9	L-Pro-OMe	L-Pro-L-Gln	2.2
L-Asn-OMe	L-Asn-L-Gln	+			
L-Gln-OMe	L-Gln-L-Gln	0.3			

(Hydrochloride salts were used for all of the carboxy components.)

5

[0093]

(Example 13) Substrate Specificity of Enzyme (4)

Peptide production by using various L-amino acid methyl esters as the carboxy component and various L-amino acids as the amine component was

10 examined. 2 μ l of the same enzyme fraction as used in Example 5 was added

to 100 μ l of 100 mM borate buffer (pH 9.0) containing 100 mM L-amino acid methyl ester hydrochlorides (AA-OMe·HCl) shown in Table 7, 150 mM L-amino acids shown in Table 7 and 10 mM EDTA, and allowed to react at 25°C for 3 hours. The amounts formed of each of the peptides formed in this reaction
5 are shown in Table 7. (The "tr" indicates a trace amount.) Note that the products when L-Asp- α,β -dimethyl ester (Asp-(OMe)₂) was used as a substrate were both α -peptide (α -Asp(β -OMe)-L-Phe) and β -peptide (β -Asp(α -OMe)-L-Phe). In total 10.1 mM, the α -peptide was 4.5 mM while the β -peptide (β -Asp(α -OMe)-L-Phe) was 5.6 mM. Furthermore, Tween-80 was
10 added to the reaction system to a final concentration of 0.1% in the case of using L-Trp-OMe. (The "+" mark indicates that peptides production was confirmed but were unable to be quantified due to the absence of a standard.)

[0094]

[Table 7]

Carboxy com- ponent	Amine com- ponent	Formed peptide	(mM)	Carboxy com- ponent	Amine com- ponent	Formed peptide	(mM)
Gly-OMe	L-CyS	Gly-L-CySH	45.6	L-Met-OMe	L-Ser	L-Met-L-Ser	12.8
	L-Arg	Gly-L-Arg	25.5		L-Met	L-Met-L-Met	25.0
	L-Phe	Gly-L-Phe	44.0		L-Phe	L-Met-L-Phe	34.0
	L-His	Gly-L-His	31.6	L-Ile-OMe	L-Ser	L-Ile-L-Ser	17.2
	L-Lys	Gly-L-Lys	9.8		L-Met	L-Ile-L-Met	10.0
	L-Ser	Gly-L-Ser	44.2		L-Phe	L-Ile-L-Phe	5.2
L-Thr-OMe	Gly	L-Thr-Gly	9.4	L-Arg-OMe	L-Ser	L-Arg-L-Ser	3.6
	L-Ala	L-Thr-L-Ala	9.4		L-Met	L-Arg-L-Met	0.7
	L-Val	L-Thr-L-Val	0.7		L-Phe	L-Arg-L-Phe	1.9
	L-Leu	L-Thr-L-Leu	28.4	L-Leu-OMe	L-Met	L-Leu-L-Met	12.2
	L-Met	L-Thr-L-Met	38.6	L-Trp-OMe	L-Met	L-Trp-L-Met	4.1
	L-Ser	L-Thr-L-Ser	58.2	L-Lys-OMe	L-Met	L-Lys-L-Met	6.8
L-Ser-OMe	L-Ser	L-Ser-L-Ser	38.0	L-His-OMe	L-Met	L-His-L-Met	6.5
	L-Met	L-Ser-L-Met	12.5	L-Asn-OMe	L-Glu	LAsn-L-Glu	10.2
	L-Phe	L-Ser-L-Phe	20.3				
L-Val-OMe	L-Ser	L-Val-L-Ser	30.8				
	L-Met	L-Val-L-Met	10.3				
	L-Phe	L-Val-L-Phe	6.1				

(Hydrochloride salts were used for all of the carboxy components.)

[0095]

(Example 14) Substrate Specificity of Enzyme (5)

Peptide production by using L or D forms of various amino acid methyl esters as the carboxy component and L or D forms of various amino acids as the amine component was examined. 2 μ l of the same enzyme fraction as used in Example 5 was added to 100 μ l of 100 mM borate buffer (pH 9.0) containing 100 mM various amino acid methyl ester hydrochlorides (AA-OMe·HCl) shown in Table 8, 150 mM various amino acids shown in Table 8 and 10 mM EDTA, and allowed to react at 25°C for 3 hours. The amounts of each of the peptides formed in this reaction are shown in Table 8. (The “tr” indicates a trace amount.)

[0096]

[Table 8]

Carboxy component	Amine component	Formed peptide (mM)	
D-Ala-OMe	L-Gln	D-Ala-L-Gln	69.3
D-Ala-OMe	L-Ser	D-Ala-L-Ser	20.3
D-Thr-OMe		D-Thr-L-Ser	1.0
D-Ser-OMe		D-Ser-L-Ser	3.3
D-Val-OMe		D-Val-L-Ser	0.6
D-Met-OMe		D-Met-L-Ser	5.1
L-Ala-OMe	D-Gln	L-Ala-D-Gln	0.3
L-Ala-OMe	D-Ser	L-Ala-D-Ser	5.4
L-Thr-OMe		L-Thr-D-Ser	6.9
L-Ser-OMe		L-Ser-D-Ser	16.2
L-Val-OMe		L-Val-D-Ser	1.4
L-Met-OMe		L-Met-D-Ser	1.9
D-Ala-OMe	D-Gln	D-Ala-D-Gln	tr
D-Ala-OMe	D-Ser	D-Ala-D-Ser	0.2
D-Thr-OMe		D-Thr-D-Ser	1.1
D-Ser-OMe		D-Ser-D-Ser	2.5
D-Val-OMe		D-Val-D-Ser	0.5
D-Met-OMe		D-Met-D-Ser	2.7

(Hydrochloride salts were used for all of the carboxy components.)

[0097]

(Example 15) Substrate Specificity of Enzyme (6)

Peptide production by using various L-amino acid amides as the carboxy component, and various L-amino acids as the amine component was examined. 2 μ l of the same enzyme fraction as that used in Example 5 was added to 100 μ l of 100 mM borate buffer (pH 9.0) containing 100 mM L-amino acid amides (AA-NH₂·HCl) shown in Table 9, 150 mM L-amino acids shown in Table 9 and 10 mM EDTA, and allowed to react at 25°C for 3 hours. The amounts of each of the peptides formed in this reaction are shown in Table 9.

10 [0098]

[Table 9]

Carboxy component	Amine component	Formed Peptide	(mM)
L-Phe-NH ₂	L-Gln	L-Phe-L-Gln	0.2
L-Phe-NH ₂	L-Ser	L-Phe-L-Ser	0.6
L-Ala-NH ₂	L-Gln	L-Ala-L-Gln	7.6
L-Ala-NH ₂	L-Met	L-Ala-L-Met	3.4
L-Ala-NH ₂	L-His	L-Ala-L-His	3.9
L-Thr-NH ₂	L-Gln	L-Thr-L-Gln	0.3

[0099]

(Example 16) Substrate Specificity of Enzyme (7)

Peptide production by using various L-alanine methyl esters as the carboxy component and C-protected L-amino acids as the amine component was examined. 2 μ l of the same enzyme fraction as used in Example 5 was added to 100 μ l of 100 mM borate buffer (pH 9.0) containing 100 mM L-amino

acid methyl ester (AA-OMe·HCl) shown in Table 10, 150 mM L-amino acid amides shown in Table 10 and 10 mM EDTA, and allowed to react at 25°C for 3 hours. The amounts of each of the peptides formed in this reaction are shown in Table 10.

5 [0100]

[Table 10]

Carboxy component	Amine component	Formed peptide	(mM)
L-Ala-OMe	Gly-NH ₂	L-Ala-Gly-NH ₂	7.4
	L-Ala-NH ₂	L-Ala-L-Ala-NH ₂	8.3
	L-Phe-NH ₂	L-Ala-L-Phe-NH ₂	12.2

[0101]

(Example 17) Substrate Specificity of Enzyme (8)

Peptide production by using various amino acid methyl esters as the carboxy component and methylamine as the amine component was examined. 2 μl of the same enzyme fraction as used in Example 5 was added to 100 μl of 100 mM borate buffer (pH 9.0) containing 100 mM amino acid methyl ester (AA-OMe·HCl) shown in Table 11, 150 mM methylamine shown in Table 11 and 10 mM EDTA, and allowed to react at 25°C for 3 hours. The amounts of each of the peptides formed in this reaction are shown in Table 11.

[0102]

[Table 11]

Carboxy component	Amine component	Formed peptide (mM)	
Gly-OMe	Methylamine	Gly-methylamine	1.1
L-Thr-OMe		L-Thr-methylamine	0.2
L-Ala-OMe		L-Ala-methylamine	0.3

[0103]

(Example 18) Substrate Specificity of Enzyme (9)

- 5 Peptide production by using β -amino acid esters as the carboxy component or β -amino acids as the amine component was examined. 2 μ l of the same enzyme fraction as used in Example 5 was added to 100 μ l of 100 mM borate buffer (pH 9.0) containing 100 mM carboxy components shown in Table 12, 150 mM amine components shown in Table 12 and 10 mM EDTA,
- 10 and allowed to react at 25°C for 3 hours. The amounts of each of the peptides formed in this reaction are shown in Table 12. (The "tr" indicates a trace amount.)

15

20

[0104]

[Table 12]

Carboxy component	Amine component	Formed peptide (mM)	
Gly-OMe	β -Ala	Gly- β -Ala	2.2
Gly-OMe	β -Phe	Gly- β -Phe	0.4
L-Ala-OMe	β -Ala	Ala- β -Ala	7.7
L-Ala-OMe	β -Phe	Ala- β -Phe	1.4
L-Thr-OMe	β -Ala	Thr- β -Ala	3.2
L-Thr-OMe	β -Phe	Thr- β -Phe	1.4
β -Ala-OMe	L-a-Ala	β -Ala-L-a-Ala	tr
β -Ala-OMe	β -Ala	β -Ala- β -Ala	0.2
B-Ala-OMe	L-Gln	β -Ala-L-Gln	0.6
B-Ala-OMe	L-Ser	β -Ala-L-Ser	3.2

[0105]

(Example 19) Substrate Specificity of Enzyme (10)

5 Oligopeptide production by using L-amino acid ester as the carboxy component and peptide as the amine component was examined. 2 μ l of the same enzyme fraction as used in Example 5 was added to 100 μ l of 100 mM borate buffer (pH 9.0) containing 100 mM carboxy components shown in Table 13, 150 mM amine components shown in Table 13 and 10 mM EDTA, and

10 allowed to react at 25°C for 3 hours. The amounts of each of the peptides formed in this reaction are shown in Table 13. As a result, it was clearly demonstrated that the present enzyme can form not only dipeptide, but also long-chain peptides by using a peptide as the amine component.

[0106]

As has been indicated in the aforementioned Examples 9 to 20, the present enzyme obtained from *Empedobacter brevis* FERM BP-8113 was determined to have extremely broad substrate specificity.

[0107]

5 [Table 13]

Carboxy component	Amine component	Produced peptide	(mM)
L-Ala-OMe	L-Ala	L-Ala-L-Ala	28.7
	L-Ala-L-Ala	L-Ala-L-Ala-L-Ala	57.5
	L-Ala-L-Ala-L-Ala	L-Ala-L-Ala-L-Ala-L-Ala	44.5
	L-Ala-L-Ala-L-Ala-L-Ala	L-Ala-L-Ala-L-Ala-L-Ala-L-Ala	34.8
	L-Ala-L-Ala-L-Ala-L-Ala-L-Ala	L-Ala-L-Ala-L-Ala-L-Ala-L-Ala-L-Ala	1.4*
	L-Ala-L-Gln	L-Ala-L-Ala-L-Gln	15.2
	Gly-L-Ala	L-Ala-Gly-L-Ala	25.9
	Gly-Gly	L-Ala-Gly-Gly	41.7
	L-His-L-Ala	L-Ala-L-His-L-Ala	55.9
	L-Leu-L-Ala	L-Ala-L-Leu-L-Ala	48.3
	L-Phe-L-Ala	L-Ala-L-Phe-L-Ala	49.7
	L-Phe-Gly	L-Ala-L-Phe-Gly	43.7
Gly-OMe	L-Ala-L-Tyr	Gly-L-Ala-L-Tyr	1.7
	Gly-L-Gln	Gly-Gly-L-Gln	7.2
	Gly-L-Tyr-L-Ala	Gly-Gly-L-Tyr-L-Ala	44.2
L-Thr-OMe	Gly-Gly	L-Thr-Gly-Gly	83.0

(*: Since the solubility of L-Ala-L-Ala-L-Ala-L-Ala-L-Ala was low, the carboxy component was used at a concentration of 10 mM and the amine component was used at 15 mM in this reaction system. The other conditions were the same as those explained in the example.)

10

[0108]

(Example 20) Comparison of Ability to Catalyze Peptide Formation with Known

Enzymes

The peptide-forming ability of the present enzyme was compared with that of known enzymes. Carboxypeptidase Y described in EP 278787A1 and the thiol endopeptidases (ficin, papain, bromelain, and chymopapain)

5 described in EP 359399B1 were used for the known enzymes, and they were used in the form of purified enzymes manufactured by Sigma.

Homogeneously purified samples were used as the enzyme in Example 3.

The enzymes were added to the reaction system. The amount of the enzyme was shown in Table 14 in terms of the amount of protein. The reaction was
10 carried out by adding the enzyme to 100 μ l of borate buffer (pH 9.0) containing 100 mM L-alanine methyl ester and 200 mM L-glutamine and allowing the resultant to react at 25°C. Note that the carboxypeptidase used was one dissolved in 10 mM acetate buffer (pH 5.0) containing 1 mM EDTA, while each thiol endopeptidase used was one dissolved in 10 mM acetate buffer (pH 5.0)
15 containing 2 mM EDTA, 0.1 M KCl, and 5 mM dithiothreitol. The ratios of the production rates of L-alanyl-L-glutamine by these enzymes are shown in Table 14.

[0109]

As a result, the production of an extremely small amount of
20 L-alanyl-L-glutamine was observed even in the absence of enzymes, while a slight increase in the production rate was observed in the carboxypeptidase- or thiol endopeptidase-added lot as compared with the enzyme-non-added lot. In contrast, an overwhelmingly higher rate of production of L-alanyl-L-glutamine was observed in the present enzyme-added lot, and that
25 rate of production was about 5,000 to 100,000 folds higher than those of

carboxypeptidase Y and thiol endopeptidases. As has been described above, the present enzyme was verified to have an extremely high peptide production rate in contrast to any known enzyme. Furthermore, the present enzyme is a dimer having a molecular weight of about 75,000. In contrast, the

5 carboxypeptidase Y has been reported to have a molecular weight of about 61,000, while the thiol endopeptidases have been reported to have a molecular weight of about 23,000 to 36,000. Thus, the present enzyme is much higher than the carboxypeptidase Y and the thiol endopeptidase when expressed in an L-alanyl-L-glutamine production rate per molecular weight as compared to

10 when expressed in L-alanyl-L-glutamine production rate per unit weight as indicated in the examples.

[0110]

[Table 14]

Enzyme	Amount of enzyme added (protein mg/ml)	L-Ala-L-Gln production rate(mM/min)	Ratio of L-Ala-L-Gln production rate per enzyme unit weight
No enzyme	0	0.0006	
Carboxypeptidase Y	0.61	0.0257	0.0191
Ficin	2.60	0.0096	0.0017
Papain	2.30	0.0106	0.0021
Bromelain	2.80	0.0062	0.0010
Chymopapain	3.60	0.0100	0.0013
Enzyme of present invention	0.02	4.4000	100.0

[0111]

- 5 (Example 21) Isolation of Peptide-forming enzyme Gene Derived from
Empedobacter brevis

Hereinafter, isolation of a peptide-forming enzyme gene will be explained. The microbe used was *Empedobacter brevis* strain FERM BP-8113. For isolating the gene, *Escherichia coli* JM-109 was used as a host
10 and pUC118 was used as a vector.

[0112]

(1) Construction of PCR Primer Based on Determined Internal Amino Acid
Sequence

A Mixed primer having the base sequences indicated in SEQ ID NO: 3
15 and SEQ ID NO: 4, respectively, was constructed based on the amino acid
sequences (SEQ ID NOs: 1 and 2) determined by the Edman's decomposition

method detecting a digestion product of a peptide-forming enzyme derived from the *Empedobacter brevis* strain FERM BP-8113 digested by a lysyl endopeptidase.

[0113]

5 (2) Preparation of Microbial Cells

Empedobacter brevis strain FERM BP-8113 was cultivated at 30°C for 24 hours on a CM2G agar medium (containing 50 g/l glucose, 10 g/l yeast extract, 10 g/l peptone, 5 g/l sodium chloride, and 20 g/l agar, pH 7.0). One loopful cells of the resulting microbial cells was inoculated into a 500 ml
10 Sakaguchi flask containing 50 ml of a CM2G liquid medium (the aforementioned medium excluding agar) followed by shaking cultivation at 30°C.

[0114]

(3) Preparation of Chromosomal DNA from Microbial Cells

15 First, 50 ml of culture broth was centrifuged (12,000 rpm, 4°C, 15 minutes) to collect the microbial cells. Then, a chromosomal DNA was obtained from the microbial cells using the QIAGEN Genomic-Tip System (Qiagen) based on the procedure described in the manual therefor.

[0115]

20 (4) Preparation of DNA Fragment Containing a Portion of Gene for Peptide-forming Enzyme by PCR

A DNA fragment containing a portion of gene for the peptide-forming enzyme derived from *Empedobacter brevis* strain FERM BP-8113 was obtained by the PCR method using LA-Taq (manufactured by Takara Shuzo).
25 A PCR reaction was then carried out by using the primers having the base

sequences of SEQ ID NOs: 3 and 4 to a chromosomal DNA obtained from *Empedobacter brevis* strain FERM BP-8113.

[0116]

The PCR reaction was carried out for 30 cycles under the following
5 conditions using Takara PCR Thermal Cycler PERSONAL (manufactured by Takara Shuzo).

94°C 30 seconds

52°C 1 minute

72°C 1 minute

10 After the reaction, 3 μ l of the reaction mixture was applied to 0.8% agarose electrophoresis. As a result, it was verified that a DNA fragment of about 1.5 kilobases (kb) was amplified.

[0117]

(5) Cloning of Gene for Peptide-Forming Enzyme from Gene Library

15 In order to obtain the gene for peptide-forming enzyme in full-length, southern hybridization was carried out by using the DNA fragment amplified in the PCR procedure as a probe. The procedure for southern hybridization is explained in Molecular Cloning, 2nd edition, Cold Spring Harbor Press (1989).

[0118]

20 The approximately 1.5 kb DNA fragment amplified by the PCR procedure was separated by 0.8% agarose electrophoresis. The target band was then cut out and purified. The DNA fragment was labeled with digoxinigen as probe by using DIG High Prime (manufactured by Boehringer-Mannheim) based on the procedure described in the manual
25 therefor.

[0119]

After completely digesting the chromosomal DNA of *Empedobacter brevis* obtained in the step (3) of the present Example 21 by reacting at 37°C for 16 hours with restriction enzyme HindIII, the resultant was electrophoresed on 0.8% agarose gel. The electrophoresed chromosomal DNA was blotted onto a positively charged Nylon membrane filter (manufactured by Roche Diagnostics) from the agarose gel after the electrophoresis, followed by treatments of alkali denaturation, neutralization and immobilization. Hybridization was carried out by using EASY HYB (manufactured by Boehringer-Mannheim). After pre-hybridizing the filter at 50°C for 1 hour, the probe labeled with digoxinigen prepared as described above was added and hybridization was carried out at 50°C for 16 hours. Subsequently, the filter was washed for 20 minutes at room temperature with 2 × SSC containing 0.1% SDS. Moreover, the filter was additionally washed twice at 65°C for 15 minutes with 1 × SSC.

[0120]

Detection of bands that hybridized with the probe was carried out by using the DIG Nucleotide Detection Kit (manufactured by Boehringer-Mannheim) based on the procedure described in the manual therefor. As a result, an about 4 kb band was able to be detected that hybridized with the probe.

[0121]

Then, 5 µg of the chromosomal DNA prepared in the step (3) of the present Example 21 was completely digested with HindIII. An about 4 kb DNA was separated by 0.8% agarose gel electrophoresis, followed by

purification of the DNA using the Gene Clean II Kit (manufactured by Funakoshi) and dissolving the DNA in 10 μ l of TE. 4 μ l of this product was then mixed with pUC118 HindIII/BAP (manufactured by Takara Shuzo) and a ligation reaction was carried out by using the DNA Ligation Kit Ver. 2

- 5 (manufactured by Takara Shuzo). 5 μ l of the ligation reaction mixture and 100 μ l of competent cells of *Escherichia coli* JM109 (manufactured by Toyobo) were mixed to transform the *Escherichia coli*. This was then applied to a suitable solid medium to construct a chromosomal DNA library.

[0122]

- 10 To obtain the full-length gene for peptide-forming enzyme, the chromosomal DNA library was screened by colony hybridization using the aforementioned probe. The procedure for colony hybridization is explained in Molecular Cloning, 2nd edition, Cold Spring Harbor Press (1989).

[0123]

- 15 The colonies of the chromosomal DNA library were transferred on a Nylon membrane filter (Nylon Membrane for Colony and Plaque Hybridization (manufactured by Roche Diagnostics) followed by treatments of alkali denaturation, neutralization and immobilization. Hybridization was carried out by using EASY HYB (manufactured by Boehringer-Mannheim). After
- 20 pre-hybridizing the filter at 37°C for 1 hour, the aforementioned probe labeled with digoxinigen was added, followed by hybridization at 50°C for 16 hours. Subsequently, the filter was washed for 20 minutes at room temperature with 2 \times SSC containing 0.1% SDS. In addition, the filter was additionally washed twice at 65°C for 15 minutes with 1 \times SSC.

- 25 [0124]

Detection of colonies hybridizing with the labeled probe was carried out by using the DIG Nucleotide Detection Kit (manufactured by Boehringer-Mannheim) based on the explanation described in the manual therefor. As a result, two strains of colonies were verified to hybridize with the
5 labeled probe.

[0125]

(6) Base Sequence of Gene for Peptide-forming enzyme Derived from
Empedobacter brevis

Plasmids possessed by *Escherichia coli* JM109 were prepared from
10 the aforementioned two strains of microbial cells that were verified to hybridize with the labeled probe by using the Wizard Plus Minipreps DNA Purification System (manufactured by Promega) and the base sequence of a portion where hybridization with the probe occurred and nearby was determined. The sequencing reaction was carried out by using the CEQ DTCS-Quick Start Kit
15 (manufactured by Beckman-Coulter) based on the procedure described in the manual therefor. In addition, electrophoresis was carried out by using the CEQ 2000-XL (manufactured by Beckman-Coulter).

[0126]

As a result, it was verified that an open reading frame that encodes a
20 protein containing the internal amino acid sequences of the peptide-forming enzyme (SEQ ID NOs: 1 and 2) did exist, and that the open reading frame was a gene encoding the peptide-forming enzyme. The base sequence of the full-length gene for peptide-forming enzyme along with the corresponding amino acid sequences is shown in SEQ ID NO: 5. As a result of analysis on
25 the homology of the resulting open reading frame with the BLASTP program,

homology was discovered with two enzymes; it showed a homology of 34% as amino acid sequence with the α -amino acid ester hydrolase of *Acetobacter pasteurianus* (see Appl. Environ. Microbiol., 68(1), 211-218 (2002), and a homology of 26% as amino acid sequence with the glutaryl-7ACA acylase of
5 *Brevibacillus laterosporum* (see J. Bacteriol., 173(24), 7848-7855 (1991).

[0127]

(Example 22) Expression of Gene for Peptide-forming Enzyme Derived from *Empedobacter brevis* in *Escherichia coli*

The promoter region of the trp operon on the chromosomal DNA of
10 *Escherichia coli* W3110 was amplified by PCR using the oligonucleotides indicated in SEQ ID NOs: 7 and 8 as primers, and the resulting DNA fragments were ligated to a pGEM-Teasy vector (manufactured by Promega).
Escherichia coli JM109 was then transformed with this ligation solution, and those strains having the target plasmid in which the direction of the inserted trp
15 promoter is opposite to the orientation of the lac promoter were selected from ampicillin-resistant strains. Next, a DNA fragment containing the trp promoter obtained by treating this plasmid with EcoO109I/EcoRI was ligated to an EcoO109I/EcoRI treatment product of pUC19 (manufactured by Takara).
Escherichia coli JM109 was then transformed with this ligation solution and
20 those strains having the target plasmid were selected from ampicillin-resistant strains. Next, a DNA fragment obtained by treating this plasmid with HindIII/PvuII was ligated to a DNA fragment containing an rrnB terminator obtained by treating pKK223-3 (manufactured by Amersham Pharmacia) with HindIII/HincII. *Escherichia coli* JM109 was then transformed with this ligation
25 solution, strains having the target plasmid were selected from

ampicillin-resistant strains, and the plasmid was designated as pTrpT.

[0128]

The target gene was amplified by PCR using the chromosomal DNA of *Empedobacter brevis* strain FERM BP-8113 as a template and the
5 oligonucleotides indicated in SEQ ID NOs: 9 and 10 as primers. This DNA
fragment was then treated with NdeI/PstI, and the resulting DNA fragment was
ligated with the NdeI/PstI treatment product of pTrpT. *Escherichia coli* JM109
was then transformed with this ligation solution, those strains having the target
plasmid were selected from ampicillin-resistant strains, and this plasmid was
10 designated as pTrpT_Gtg2.

[0129]

Escherichia coli JM109 having pTrpT_Gtg2 was seed cultured at 30°C
for 24 hours in LB medium containing 100 mg/l of ampicillin. 1 ml of the
resulting culture broth was transferred in a 500 ml Sakaguchi flask containing
15 50 ml of a medium (D-glucose 2 g/l, yeast extract 10 g/l, casamino acid 10 g/l,
ammonium sulfate 5 g/l, potassium dihydrogen phosphate 3 g/l, dipotassium
hydrogen phosphate 1 g/l, magnesium sulfate heptahydrate 0.5 g/l, and
ampicillin 100 mg/l), followed by cultivation at 25°C for 24 hours. The culture
broth had an L-alanyl-L-glutamine production activity of 0.44 U per ml of culture
20 broth and it was verified that the cloned gene was expressed by *Escherichia*
coli. Furthermore, no activity was detected for a transformant in which only
pTrpT had been introduced as a control.

[0130]

(Example 23) Production of L-Alanyl-L-Glutamine Using Microbial Cells of
25 *Sphingobacterium* sp.

A 50 ml medium (pH 7.0) containing 5 g glucose, 5 g ammonium sulfate, 1 g monopotassium phosphate, 3 g dipotassium phosphate, 0.5 g magnesium sulfate, 10 g yeast extract and 10 g peptone in 1 L was transferred to a 500 mL Sakaguchi flask and sterilized at 115°C for 15 minutes for culturing *Sphingobacterium* sp. strain FERM BP-8124. This was then inoculated with one loopful cells of *Sphingobacterium* sp. strain FERM BP-8124 cultivated at 30°C for 24 hours on a slant agar medium (pH 7.0) containing 5 g glucose, 10 g yeast extract, 10 g peptone and 5 g NaCl and 20 g/L agar in 1 L, followed by shaking cultivation at 30°C for 20 hours and 120 strokes/minute. 1 ml of this culture broth was then added to the aforementioned medium (50 ml/500 mL Sakaguchi flask) and cultivated at 30°C for 18 hours. After the cultivation, the microbial cells were separated from the culture broth by centrifugation and suspended in 0.1 M borate buffer (pH 9.0) containing 10 mM EDTA to 100 g/L cells as wet basis. 0.1 mL of 100 mM borate buffer (pH 9.0) containing 10 mM EDTA, 200 mM L-alanyl methyl ester hydrochloride and 400 mM L-glutamine was then added to 0.1 mL of this microbial cell suspension to bring a final volume 0.2 mL, was allowed to react at 25°C for 120 minutes. The amount of L-alanyl-L-glutamine formed was 62 mM.

[0131]

(Example 24) Purification of Enzyme from *Sphingobacterium* sp.

The following procedure after centrifugal separation was carried out either on ice or at 4°C. *Sphingobacterium* sp. FERM BP-8124 was cultivated in the same manner as Example 23, and the microbial cells were collected by centrifugal separation (10,000 rpm, 15 minutes). After washing 2 g of microbial cells with 20 mM Tris-HCl buffer (pH 7.6), they were suspended in 8

ml of the same buffer and subjected to ultrasonic disrupting treatment for 45 minutes at 195 W. This ultrasonically disrupted solution was then centrifuged (10,000 rpm, 30 minutes) to remove the cell debris and obtain an ultrasonically disrupted supernatant. This supernatant was dialyzed overnight against 20 mM Tris-HCl buffer (pH 7.6) followed by removal of the insoluble fraction by ultracentrifugation (50,000 rpm, 30 minutes) to obtain a soluble fraction in the form of the supernatant solution. The resulting soluble fraction was applied to a Q-Sepharose HP column (manufactured by Amersham) pre-equilibrated with Tris-HCl buffer (pH 7.6), and the active fraction was collected from the non-adsorbed fraction. This active fraction was dialyzed overnight against 20 mM acetate buffer (pH 5.0) followed by removal of the insoluble fraction by centrifugal separation (10,000 rpm, 30 minutes) to obtain a dialyzed fraction in the form of the supernatant solution. This supernatant was then applied to an SP-Sepharose HP column (manufactured by Amersham) pre-equilibrated with 20 mM acetate buffer (pH 5.0) to obtain the active fraction in which enzyme was eluted with a linear concentration gradient of the same buffer containing 0 to 1 M NaCl.

[0132]

(Example 25) Production of L-Alanyl-L-Glutamine Using Enzyme Fraction

10 μ l of the SP-Sepharose HP fraction (about 27 U/ml) purified in Example 24 was added to 90 μ l of 111 mM borate buffer (pH 9.0) containing 111 mM L-alanine methyl ester hydrochloride, 222 mM L-glutamine and 11 mM EDTA, and allowed to react at 25°C for 120 minutes. As a result, 73 mM of L-alanyl-L-glutamine was formed in the enzyme-added lot. On the other hand, there was scarcely any production of L-Ala-L-Glu observed in the

enzyme-non-added lot, and the production amount was only about 0.07 mM after reaction for 120 minutes.

[0133]

(Example 26) Isolation of Gene for Peptide-forming Enzyme Derived from

5 *Sphingobacterium* sp.

Hereinafter, isolation of gene for a peptide-forming enzyme is described. The microbe used was *Sphingobacterium* sp. strain FERM BP-8124. For the isolation of gene, *Escherichia coli* DH5 α was used as a host, and pUC118 was used as a vector.

10 [0134]

(1) Preparation of Microbial Cells

Sphingobacterium sp. strain FERM BP-8124 was cultivated for 24 hours at 25°C on CM2G agar medium (containing glucose 50 g/l, yeast extract 10 g/l, peptone 10 g/l, sodium chloride 5 g/l, and agar 20 g/l, pH 7.0). One
15 loopful cells of the resulting microbial cells was inoculated into a 500 ml Sakaguchi flask containing 50 ml of CM2G liquid medium (the aforementioned medium excluding agar) followed by shaking cultivation at 25°C.

[0135]

(2) Preparation of Chromosomal DNA from Microbial Cells

20 50 ml of culture broth was centrifuged (12,000 rpm, 4°C, 15 minutes) to collect the microbial cells. A chromosomal DNA was then obtained from the microbial cells using the Qiagen Genomic-Tip System (Qiagen) based on the procedure described in the manual therefor.

[0136]

25 (3) Preparation of Probe DNA Fragment by PCR

A DNA fragment containing a portion of gene for the peptide-forming enzyme derived from *Empedobacter brevis* FERM BP-8113 was obtained by the PCR method using LA-Taq (manufactured by Takara Shuzo). A PCR reaction was then carried out by using primers having the base sequences of
5 SEQ ID NOs: 3 and 4 to the chromosomal DNA obtained from *Empedobacter brevis* strain FERM BP-8113.

[0137]

The PCR reaction was carried out by using Takara PCR Thermal
Cycler – PERSONAL (Takara Shuzo) for 30 cycles under the following
10 conditions.

94°C 30 seconds

52°C 1 minute

72°C 1 minute

After the reaction, 3 µl of reaction mixture was applied to 0.8% agarose
15 electrophoresis. As a result, it was verified that a DNA fragment of about 1.5 kb was amplified.

[0138]

(4) Cloning of Gene for Peptide-forming enzyme from Gene Library

In order to obtain the full-length gene for peptide-forming enzyme,
20 southern hybridization was carried out by using the DNA fragment amplified in the aforementioned PCR procedure as a probe. The procedure of southern hybridization are explained in Molecular Cloning, 2nd edition, Cold Spring Harbor Press (1989).

[0139]

25 The approximately 1.5 kb DNA fragment amplified by the

aforementioned PCR procedure was separated by 0.8% agarose electrophoresis. The target band was then cut out and purified. This DNA fragment was labeled with digoxinigen as probe by using DIG High Prime (manufactured by Boehringer-Mannheim) based on the procedure described in the manual therefor.

[0140]

After allowing the chromosomal DNA of *Sphingobacterium* sp. obtained in the step (2) of the present Example 23 to react with restriction enzyme *SacI* at 37°C for 16 hours to completely digest the DNA, the resultant was electrophoresed on 0.8% agarose gel. From the agarose gel after the electrophoresis, the electrophoresed chromosomal DNA was blotted onto a positively charged Nylon membrane filter (manufactured by Roche Diagnostics), followed by treatments consisting of alkali denaturation, neutralization, and immobilization. Hybridization was carried out by using EASY HYB (manufactured by Boehringer-Mannheim). After pre-hybridizing the filter at 37°C for 1 hour, the digoxinigen-labeled probe prepared as described above was added and hybridization was carried out at 37°C for 16 hours. Subsequently, the filter was washed twice at 60°C with 2 × SSC containing 0.1% SDS.

[0141]

Detection of bands that hybridized with the probe was carried out by using the DIG Nucleotide Detection Kit (Boehringer-Mannheim) based on the procedure described in the manual therefor. As a result, an about 3 kb band was successfully detected that hybridized with the probe.

[0142]

5 μ g of the chromosomal DNA prepared in the step (2) of the present Example 23 was completely digested with *SacI*. About 3 kb of a DNA was separated by 0.8% agarose gel electrophoresis, the DNA was purified using the Gene Clean II Kit (manufactured by Funakoshi), and dissolved in 10 μ l of TE. 4 μ l of the resulting solution was mixed with pUC118 that had been allowed to react treated with *SacI* at 37°C for 16 hours to completely digest it and then treated with alkaline phosphatase (*E. coli* C75) at 37°C for 30 minutes and at 50°C for 30 minutes and a ligation reaction was carried out by using the DNA Ligation Kit Ver. 2 (manufactured by Takara Shuzo). 5 μ l of this ligation reaction mixture and 100 μ l of competent cells of *Escherichia coli* DH5 α (manufactured by Takara Shuzo) were mixed to transform the *Escherichia coli*. This was then applied to a suitable solid medium to produce a chromosomal DNA library.

[0143]

15 To obtain full-length gene for peptide-forming enzyme, the chromosomal DNA library was screened by colony hybridization using the aforementioned probe. The procedure for colony hybridization is explained in Molecular Cloning, 2nd edition, Cold Spring Harbor Press (1989).

[0144]

20 The colonies of the chromosomal DNA library were transferred on a Nylon membrane filter (Nylon Membrane for Colony and Plaque Hybridization, manufactured by Roche Diagnostics), followed by treatments of alkali denaturation, neutralization, and immobilization. Hybridization was carried out by using EASY HYB (manufactured by Boehringer-Mannheim). After
25 pre-hybridizing the filter at 37°C for 1 hour, the aforementioned

digoxinigen-labeled probe was added, followed by hybridization at 37°C for 16 hours. Subsequently, the filter was washed twice at 60°C with 1 × SSC containing 0.1% SDS.

[0145]

5 Detection of colonies hybridizing with the labeled probe was carried out by using the DIG Nucleotide Detection Kit (manufactured by Boehringer-Mannheim) based on the explanation described in the manual therefor. As a result, six strains of colonies were verified to have hybridized with the labeled probe.

10 [0146]

(5) Base Sequence of Gene for Peptide-forming Enzyme Derived from *Sphingobacterium* sp.

Plasmids possessed by *Escherichia coli* DH5α were prepared from the six strains of microbial cells that were verified to have hybridized with the
15 labeled probe by using the Wizard Plus Minipreps DNA Purification System (manufactured by Promega) to determine the base sequence of a portion where hybridization with the probe occurred and nearby was determined. The sequencing reaction was carried out by using the CEQ DTCS-Quick Start Kit (manufactured by Beckman-Coulter) based on the procedure described in the
20 manual therefor. In addition, electrophoresis was carried out by using the CEQ 2000-XL (manufactured by Beckman-Coulter).

[0147]

As a result, it revealed that an open reading frame that encodes peptide-forming enzyme did exist. The full-length base sequence of gene for
25 the peptide-forming enzyme derived from *Sphingobacterium* sp. along with the

corresponding amino acid sequence is shown in SEQ ID NO: 11.

Peptide-forming enzyme derived from *Sphingobacterium* sp. exhibited a homology of 63.5% at the amino acid sequence level to the peptide-forming enzyme derived from *Empedobacter brevis* (as determined using the BLASTP program).

[0148]

(Example 27) Expression of Gene for Peptide-forming Enzyme Derived from *Sphingobacterium* sp. in *Escherichia coli*

The target gene was amplified by PCR using the chromosomal DNA of *Sphingobacterium* sp. FERM BP-8124 as a template and the oligonucleotides shown in SEQ ID NOs: 13 and 14 as primers. This DNA fragment was treated with NdeI/XbaI, and the resulting DNA fragment and an NdeI/XbaI treatment product of pTrpT were ligated. *Escherichia coli* JM109 was then transformed with this ligation solution, and strains having the target plasmid were selected from ampicillin-resistant strains. The plasmid was designated as pTrpT_Sm_aet.

[0149]

One loopful cells of *Escherichia coli* JM109 having pTrpT_Sm_aet was inoculated into an ordinary test tube containing 3 ml of a medium (glucose 2 g/l, yeast extract 10 g/l, casamino acid 10 g/l, ammonium sulfate 5 g/l, potassium dihydrogen phosphate 3 g/l, dipotassium hydrogen phosphate 1 g/l, magnesium sulfate heptahydrate 0.5 g/l and ampicillin 100 mg/l) and the cultivation was performed at 25°C for 20 hours. It was verified that a cloned gene having an L-alanyl-L-glutamine production activity of 2.1 U per ml of culture broth was expressed by *Escherichia coli*. Furthermore, no activity was

detected for a transformant containing only pTrpT used as a control.

[0150]

[Effects due to the Invention]

According to the present invention, tripeptides can be produced easily
5 using enzymes. According to the method of the present invention, peptides
that are equal to or longer than tripeptides can be produced easily,
inexpensively in high yields while mitigating complex synthesis methods such
as introduction and elimination of protecting groups.

[0151]

10 [Sequence Listing]

SEQUENCE LISTING

<110> AJINOMOTO CO., INC.

15 <120> METHOD FOR PRODUCING TRIPEPTIDES AND/OR PEPTIDES LONGER THAN TRIPEPTIDE
S

<130> PAMA-15009

20 <150> JP2002-218958

<151> 2002-07-26

<160> 14

25 <170> PatentIn Ver. 2.1

<210> 1

<211> 9

<212> PRT

30 <213> Empedobacter brevis

<220>

<223> Inventor: YOKOZEKI, Kenzo
Inventor: SUZUKI, Sonoko
Inventor: HARA, Seiichi
Inventor: ABE, Isao

5

<400> 1
Leu Phe Thr Ala Ile Tyr Gln Pro Lys
1 5

10

<210> 2
<211> 9
<212> PRT
<213> Empedobacter brevis

15

<400> 2
Thr Asn Val Thr Tyr Thr Met Pro Asp
1 5

20

<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence

25

<220>
<223> Description of Artificial Sequence: synthesized
primer 1

30

<400> 3
ttyacngcna thtaylorcc

20

35

<210> 4
<211> 23
<212> DNA
<213> Artificial Sequence

<220>

```

<223> Description of Artificial Sequence:synthesized
        primer 2

<400> 4
5  tcnggcatng trtangtnac rtt                                     23

<210> 5
<211> 2024
10 <212> DNA
    <213> Empedobacter brevis

<220>
<221> CDS
15 <222> (61)..(1908)
    <223> gene coding  peptide synthase

<400> 5
    atttcttaat aaaaactgaa atcttaatac atttatacta tcgtaaaatt tattgaacac 60
20
    gtg aaa aaa tta aca tta aaa gta act cta ctt aca ctt ttg ttg gga 108
    Val Lys Lys Leu Thr Leu Lys Val Thr Leu Leu Thr Leu Leu Leu Gly
        1          5          10          15

25 agt aca gtt gga ttt gcg caa gat gca aaa gca gat tct gct tat gtg 156
    Ser Thr Val Gly Phe Ala Gln Asp Ala Lys Ala Asp Ser Ala Tyr Val
        20          25          30

    cgc gac aat tac gaa aaa ata gaa caa gta att ccg atg cgc gat ggt 204
30 Arg Asp Asn Tyr Glu Lys Ile Glu Gln Val Ile Pro Met Arg Asp Gly
        35          40          45

    aca aag tta ttt aca gct att tat cag cca aaa gat aaa aca aaa caa 252
    Thr Lys Leu Phe Thr Ala Ile Tyr Gln Pro Lys Asp Lys Thr Lys Gln
35          50          55          60

    tat ccc gtt ttg tta aat cgt acg cct tat aca gtt gcg cct tat ggt 300
    Tyr Pro Val Leu Leu Asn Arg Thr Pro Tyr Thr Val Ala Pro Tyr Gly
        65          70          75          80

```

	gta aat gaa tac aag aaa tcg tta gga aat ttt cct aca gaa atg cgc	348
	Val Asn Glu Tyr Lys Lys Ser Leu Gly Asn Phe Pro Thr Glu Met Arg	
	85 90 95	
5		
	gaa ggt ttt att ttt gtt tac caa gat gtg aga gga aaa tgg atg agc	396
	Glu Gly Phe Ile Phe Val Tyr Gln Asp Val Arg Gly Lys Trp Met Ser	
	100 105 110	
10		
	gaa ggc gaa ttt gaa gat gtt cga cct ata aat cct tca aaa agt aaa	444
	Glu Gly Glu Phe Glu Asp Val Arg Pro Ile Asn Pro Ser Lys Ser Lys	
	115 120 125	
15		
	aag gca att gac gaa agc aca gat aca ttt gat acg cta gaa tgg ctt	492
	Lys Ala Ile Asp Glu Ser Thr Asp Thr Phe Asp Thr Leu Glu Trp Leu	
	130 135 140	
20		
	gct aaa aac ttg aag aat tac acg aaa aaa gct gga att tat gga att	540
	Ala Lys Asn Leu Lys Asn Tyr Thr Lys Lys Ala Gly Ile Tyr Gly Ile	
	145 150 155 160	
25		
	tcg tat cct ggt ttt tat tcg aca atg agt ttg gtt aat tcg cat cca	588
	Ser Tyr Pro Gly Phe Tyr Ser Thr Met Ser Leu Val Asn Ser His Pro	
	165 170 175	
30		
	act cta aaa gcc gtt tcg cca caa gcg ccc gtt acc aat tgg ttt tta	636
	Thr Leu Lys Ala Val Ser Pro Gln Ala Pro Val Thr Asn Trp Phe Leu	
	180 185 190	
35		
	ggt gac gat ttt cat cat aat gga gtt tta ttc ttg aat gat tct ttc	684
	Gly Asp Asp Phe His His Asn Gly Val Leu Phe Leu Asn Asp Ser Phe	
	195 200 205	
40		
	tca ttt atg act ttt ttt ggt gta aaa cgt ccg caa cca att acg cca	732
	Ser Phe Met Thr Phe Phe Gly Val Lys Arg Pro Gln Pro Ile Thr Pro	
	210 215 220	
45		
	gat aaa ggt ccg aaa cgt ttt gaa tat cca ata aaa gat aat tat aga	780
	Asp Lys Gly Pro Lys Arg Phe Glu Tyr Pro Ile Lys Asp Asn Tyr Arg	

	225	230	235	240	
	ttt tat gca agt ggc tct gta aaa gag ttg aaa gat aaa tat ttg caa Phe Tyr Ala Ser Gly Ser Val Lys Glu Leu Lys Asp Lys Tyr Leu Gln				828
5		245	250	255	
	gat aat atc aag ttt tac aat gat tta ttt gcg cat cca gat tac gat Asp Asn Ile Lys Phe Tyr Asn Asp Leu Phe Ala His Pro Asp Tyr Asp				876
		260	265	270	
10	caa ttt tgg caa gat cgt aat gtt tta cca cat tta act aac gtg caa Gln Phe Trp Gln Asp Arg Asn Val Leu Pro His Leu Thr Asn Val Gln				924
		275	280	285	
15	cct gct gta atg acg gtt gga ggt ttt ttt gat gca gaa gat gtc tac Pro Ala Val Met Thr Val Gly Gly Phe Phe Asp Ala Glu Asp Val Tyr				972
		290	295	300	
	ggc gct ttc gaa acg tat aaa gca att gag aaa caa aat ccg aaa gca Gly Ala Phe Glu Thr Tyr Lys Ala Ile Glu Lys Gln Asn Pro Lys Ala				1020
20		305	310	315	320
	aca aat att atg gtt gcc gga cct tgg ttt cat ggt ggt tgg gtt cgt Thr Asn Ile Met Val Ala Gly Pro Trp Phe His Gly Gly Trp Val Arg				1068
25		325	330	335	
	agc aac gga agt act ttt gga gat atg caa ttt gca tcg aat aca agt Ser Asn Gly Ser Thr Phe Gly Asp Met Gln Phe Ala Ser Asn Thr Ser				1116
		340	345	350	
30	gag cat tat cag caa gaa ata gaa ttg cct ttt ttt aat tat tac tta Glu His Tyr Gln Gln Glu Ile Glu Leu Pro Phe Phe Asn Tyr Tyr Leu				1164
		355	360	365	
35	aaa gat aaa ggt aat ttt aaa cca acc gaa gct aca att ttt att acg Lys Asp Lys Gly Asn Phe Lys Pro Thr Glu Ala Thr Ile Phe Ile Thr				1212
		370	375	380	
	gga tct aac gaa tgg aaa caa ttt gat gct tgg cca cca aaa aat gta				1260

aat aaa gaa aca aat gta acg tac acg atg cca gat gtt gga cat aca 1740
 Asn Lys Glu Thr Asn Val Thr Tyr Thr Met Pro Asp Val Gly His Thr
 545 550 555 560

5 ttt aag aaa gga cat cgc att atg att caa gtt cag aac agt tgg ttt 1788
 Phe Lys Lys Gly His Arg Ile Met Ile Gln Val Gln Asn Ser Trp Phe
 565 570 575

10 cct tta gca gat cgc aat ccg caa caa ttt atg aat gtt tac gaa gca 1836
 Pro Leu Ala Asp Arg Asn Pro Gln Gln Phe Met Asn Val Tyr Glu Ala
 580 585 590

15 act tct aaa gat tat tta aaa caa acg caa cga att tat cat act tct 1884
 Thr Ser Lys Asp Tyr Leu Lys Gln Thr Gln Arg Ile Tyr His Thr Ser
 595 600 605

20 tat atc gaa att ccg gta ttg aaa taacaaaaaaaa atccagctaa ttagctggat 1938
 Tyr Ile Glu Ile Pro Val Leu Lys
 610 615

tttttttata atgttacttt tcctattttt cctttatttc caactaaaat tacatatattt 1998

ttatcggggcg aaaccgtaca agtatg 2024

25
 <210> 6
 <211> 616
 <212> PRT
 <213> Empedobacter brevis

30
 <400> 6
 Val Lys Lys Leu Thr Leu Lys Val Thr Leu Leu Thr Leu Leu Leu Gly
 1 5 10 15

35 Ser Thr Val Gly Phe Ala Gln Asp Ala Lys Ala Asp Ser Ala Tyr Val
 20 25 30

Arg Asp Asn Tyr Glu Lys Ile Glu Gln Val Ile Pro Met Arg Asp Gly
 35 40 45

Thr Lys Leu Phe Thr Ala Ile Tyr Gln Pro Lys Asp Lys Thr Lys Gln
 50 55 60

5 Tyr Pro Val Leu Leu Asn Arg Thr Pro Tyr Thr Val Ala Pro Tyr Gly
 65 70 75 80

Val Asn Glu Tyr Lys Lys Ser Leu Gly Asn Phe Pro Thr Glu Met Arg
 85 90 95

10 Glu Gly Phe Ile Phe Val Tyr Gln Asp Val Arg Gly Lys Trp Met Ser
 100 105 110

Glu Gly Glu Phe Glu Asp Val Arg Pro Ile Asn Pro Ser Lys Ser Lys
 15 115 120 125

Lys Ala Ile Asp Glu Ser Thr Asp Thr Phe Asp Thr Leu Glu Trp Leu
 130 135 140

20 Ala Lys Asn Leu Lys Asn Tyr Thr Lys Lys Ala Gly Ile Tyr Gly Ile
 145 150 155 160

Ser Tyr Pro Gly Phe Tyr Ser Thr Met Ser Leu Val Asn Ser His Pro
 165 170 175

25 Thr Leu Lys Ala Val Ser Pro Gln Ala Pro Val Thr Asn Trp Phe Leu
 180 185 190

Gly Asp Asp Phe His His Asn Gly Val Leu Phe Leu Asn Asp Ser Phe
 30 195 200 205

Ser Phe Met Thr Phe Phe Gly Val Lys Arg Pro Gln Pro Ile Thr Pro
 210 215 220

35 Asp Lys Gly Pro Lys Arg Phe Glu Tyr Pro Ile Lys Asp Asn Tyr Arg
 225 230 235 240

Phe Tyr Ala Ser Gly Ser Val Lys Glu Leu Lys Asp Lys Tyr Leu Gln
 245 250 255

	Asp Asn Ile Lys Phe Tyr Asn Asp Leu Phe Ala His Pro Asp Tyr Asp		
	260	265	270
5	Gln Phe Trp Gln Asp Arg Asn Val Leu Pro His Leu Thr Asn Val Gln		
	275	280	285
	Pro Ala Val Met Thr Val Gly Gly Phe Phe Asp Ala Glu Asp Val Tyr		
	290	295	300
10	Gly Ala Phe Glu Thr Tyr Lys Ala Ile Glu Lys Gln Asn Pro Lys Ala		
	305	310	315 320
	Thr Asn Ile Met Val Ala Gly Pro Trp Phe His Gly Gly Trp Val Arg		
15	325	330	335
	Ser Asn Gly Ser Thr Phe Gly Asp Met Gln Phe Ala Ser Asn Thr Ser		
	340	345	350
20	Glu His Tyr Gln Gln Glu Ile Glu Leu Pro Phe Phe Asn Tyr Tyr Leu		
	355	360	365
	Lys Asp Lys Gly Asn Phe Lys Pro Thr Glu Ala Thr Ile Phe Ile Thr		
	370	375	380
25	Gly Ser Asn Glu Trp Lys Gln Phe Asp Ala Trp Pro Pro Lys Asn Val		
	385	390	395 400
	Thr Thr Gln Lys Ile Tyr Leu Gln Gln Asn Gly Lys Ile Ala Phe Asn		
30	405	410	415
	Lys Thr Asn Thr Thr Thr Thr Phe Asp Glu Tyr Val Ala Asp Pro Asn		
	420	425	430
35	Ser Pro Val Pro Tyr Ser Gly Gly Val Leu Glu Thr Arg Ser Arg Glu		
	435	440	445
	Tyr Met Val Asp Asp Gln Arg Phe Ala Ser Thr Arg Pro Asp Val Met		
	450	455	460

	Val Tyr Gln Ser Asp Ile Leu Thr Glu Asp Ile Thr Leu Ala Gly Pro	
	465	475 480
5	Val Ile Asn His Leu Val Val Ser Thr Thr Gly Thr Asp Ala Asp Tyr	
	485	490 495
	Val Val Lys Leu Ile Asp Val Tyr Pro Glu Asn Thr Pro Lys Phe Asn	
	500	505 510
10	Asn Lys Leu Met Ala Gly Tyr Gln Asn Leu Ile Arg Ala Glu Ile Met	
	515	520 525
	Arg Gly Lys Tyr Arg Asn Ser Phe Ser Asn Pro Glu Ala Met Val Pro	
15	530	535 540
	Asn Lys Glu Thr Asn Val Thr Tyr Thr Met Pro Asp Val Gly His Thr	
	545	550 555 560
20	Phe Lys Lys Gly His Arg Ile Met Ile Gln Val Gln Asn Ser Trp Phe	
	565	570 575
	Pro Leu Ala Asp Arg Asn Pro Gln Gln Phe Met Asn Val Tyr Glu Ala	
	580	585 590
25	Thr Ser Lys Asp Tyr Leu Lys Gln Thr Gln Arg Ile Tyr His Thr Ser	
	595	600 605
	Tyr Ile Glu Ile Pro Val Leu Lys	
30	610	615
	<210> 7	
35	<211> 40	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	

<223> Description of Artificial Sequence:synthesized
primer for preparation of pTrpT

<400> 7

5 gtatcacgag gccctagctg tgggtgcatg gtcggtgatc 40

<210> 8

<211> 40

10 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthesized
15 primer for preparation of pTrpT

<400> 8

ttcgggggatt ccatatgata ccctttttac gtgaacttgc 40

20

<210> 9

<211> 38

<212> DNA

<213> Artificial Sequence

25

<220>

<223> Description of Artificial Sequence:synthesized
primer for preparation of pTrpT_Gtg2

30 <400> 9

gggaattcca tatgaaaaaa ttaacattaa aagtaact 38

<210> 10

35 <211> 36

<212> DNA

<213> Artificial Sequence

<220>

```

<223> Description of Artificial Sequence:synthesized
        primer for preparation of pTrpT_Gtg2

<400> 10
5  gggggctgca gtacttgtag ggtttcgccc gataaa 36

<210> 11
<211> 1935
10 <212> DNA
    <213> Sphingobacterium sp.

<220>
<221> CDS
15 <222> (61)..(1917)
    <223> gene of peptide synthase

<400> 11
20 gaaaccaagt gtaaaattat aatttacacc aaagaatgta ctgaacaaat aattatctga 60

    atg aaa aat aca att tcg tgc cta act tta gcg ctt tta agc gca agc 108
    Met Lys Asn Thr Ile Ser Cys Leu Thr Leu Ala Leu Leu Ser Ala Ser
        1             5             10             15

25 cag tta cat gct caa aca gct gcc gac tcg gct tat gtt aga gat cat 156
    Gln Leu His Ala Gln Thr Ala Ala Asp Ser Ala Tyr Val Arg Asp His
            20             25             30

    tat gaa aag acc gaa gta gca att ccc atg cga gat ggg aaa aaa tta 204
30 Tyr Glu Lys Thr Glu Val Ala Ile Pro Met Arg Asp Gly Lys Lys Leu
        35             40             45

    ttt act gcg atc tac agt cca aaa gac aaa tcc aag aaa tat cca gtt 252
35 Phe Thr Ala Ile Tyr Ser Pro Lys Asp Lys Ser Lys Lys Tyr Pro Val
        50             55             60

    ttg ctc aat aga acg ccc tac acg gtt tca cct tat ggg cag aac gaa 300
    Leu Leu Asn Arg Thr Pro Tyr Thr Val Ser Pro Tyr Gly Gln Asn Glu
        65             70             75             80

```

	tat aaa aaa agc ttg gga aac ttt ccc caa atg atg cgt gaa ggc tat	348
	Tyr Lys Lys Ser Leu Gly Asn Phe Pro Gln Met Met Arg Glu Gly Tyr	
	85 90 95	
5		
	att ttc gtt tac cag gat gtc cgt ggc aag tgg atg agc gaa ggt gat	396
	Ile Phe Val Tyr Gln Asp Val Arg Gly Lys Trp Met Ser Glu Gly Asp	
	100 105 110	
10		
	ttt gaa gat ata cgt ccg acc acg tac agc aaa gat aaa aaa gca atc	444
	Phe Glu Asp Ile Arg Pro Thr Thr Tyr Ser Lys Asp Lys Lys Ala Ile	
	115 120 125	
15		
	gat gaa agt acg gat acc tat gat gcg ctt gaa tgg tta cag aaa aat	492
	Asp Glu Ser Thr Asp Thr Tyr Asp Ala Leu Glu Trp Leu Gln Lys Asn	
	130 135 140	
20		
	ctc aaa aac tat aat ggc aaa gcc ggg ctc tat ggg att tcc tat cca	540
	Leu Lys Asn Tyr Asn Gly Lys Ala Gly Leu Tyr Gly Ile Ser Tyr Pro	
	145 150 155 160	
25		
	ggc ttc tat tct acc gtc gga ttg gtc aaa aca cac ccg agc ttg aag	588
	Gly Phe Tyr Ser Thr Val Gly Leu Val Lys Thr His Pro Ser Leu Lys	
	165 170 175	
30		
	gca gtc tcc cca cag gct ccc gta aca gac tgg tat atc ggc gac gac	636
	Ala Val Ser Pro Gln Ala Pro Val Thr Asp Trp Tyr Ile Gly Asp Asp	
	180 185 190	
35		
	ttc cac cat aat ggc gta ttg ttt ctt cag gat gca ttt aca ttc atg	684
	Phe His His Asn Gly Val Leu Phe Leu Gln Asp Ala Phe Thr Phe Met	
	195 200 205	
	tca acc ttt ggt gtc cct cgt cca aaa ccc att aca ccg gat caa ttt	732
	Ser Thr Phe Gly Val Pro Arg Pro Lys Pro Ile Thr Pro Asp Gln Phe	
	210 215 220	
	aag ggc aaa att cag atc aaa gaa gcc gat aaa tat aac ttt ttt gca	780
	Lys Gly Lys Ile Gln Ile Lys Glu Ala Asp Lys Tyr Asn Phe Phe Ala	

	225	230	235	240	
	gaa gca gga aca gcg cgg gaa ctc aaa gaa aag tat ttt ggt gac tcc				828
	Glu Ala Gly Thr Ala Arg Glu Leu Lys Glu Lys Tyr Phe Gly Asp Ser				
5	245		250	255	
	gta caa ttt tgg aat gac ctg ttt aag cat ccc gac tat gat gat ttt				876
	Val Gln Phe Trp Asn Asp Leu Phe Lys His Pro Asp Tyr Asp Asp Phe				
	260		265	270	
10	tgg aaa tcg cgt gtg atc acg aat tct tta cag gag gta aaa cca gct				924
	Trp Lys Ser Arg Val Ile Thr Asn Ser Leu Gln Glu Val Lys Pro Ala				
	275		280	285	
15	gtg atg gtg gtt ggt ggt ttc ttt gac gcg gaa gat gct tat gga aca				972
	Val Met Val Val Gly Gly Phe Phe Asp Ala Glu Asp Ala Tyr Gly Thr				
	290		295	300	
	ttt aag acc tac caa tcg att gag gat aaa agc aaa aaa aac aac tcg				1020
20	Phe Lys Thr Tyr Gln Ser Ile Glu Asp Lys Ser Lys Lys Asn Asn Ser				
	305		310	315	320
	att tta gtc gcg gga cct tgg tat cat ggc ggt tgg gtt cgt gca gaa				1068
	Ile Leu Val Ala Gly Pro Trp Tyr His Gly Gly Trp Val Arg Ala Glu				
25	325		330	335	
	gga aac tat tta ggt gat atc caa ttt gag aaa aaa acc agt att act				1116
	Gly Asn Tyr Leu Gly Asp Ile Gln Phe Glu Lys Lys Thr Ser Ile Thr				
	340		345	350	
30	tat cag gaa caa ttt gaa caa cca ttt ttc aaa tat tac cta aaa gat				1164
	Tyr Gln Glu Gln Phe Glu Gln Pro Phe Phe Lys Tyr Tyr Leu Lys Asp				
	355		360	365	
35	gaa gga aac ttc gcc cct tcc gaa gct aac att ttt gtt tca ggc agc				1212
	Glu Gly Asn Phe Ala Pro Ser Glu Ala Asn Ile Phe Val Ser Gly Ser				
	370		375	380	
	aac gaa tgg aaa cat ttc gaa cag tgg cca cca aaa aat gta gag aca				1260

gtc gaa aag gtg aat ttt gaa atg cca gac gtt gcg cat acc ttc aaa 1740
 Val Glu Lys Val Asn Phe Glu Met Pro Asp Val Ala His Thr Phe Lys
 545 550 555 560

5 aaa gga cat cgc att atg gtt cag gta caa aac tca tgg ttt ccg ctg 1788
 Lys Gly His Arg Ile Met Val Gln Val Gln Asn Ser Trp Phe Pro Leu
 565 570 575

10 gca gaa cga aat cca cag gtg ttt tta gca cct tat aca gct acc aaa 1836
 Ala Glu Arg Asn Pro Gln Val Phe Leu Ala Pro Tyr Thr Ala Thr Lys
 580 585 590

15 gct gat ttc cgc aaa gct acc caa cgt att ttt cac gat gtg aac aat 1884
 Ala Asp Phe Arg Lys Ala Thr Gln Arg Ile Phe His Asp Val Asn Asn
 595 600 605

20 gcc aca tac atc gaa ttt tct gtc ctc aaa gat tagcaggtaa attcgaaa 1935
 Ala Thr Tyr Ile Glu Phe Ser Val Leu Lys Asp
 610 615

<210> 12
 <211> 619
 <212> PRT
 25 <213> Sphingobacterium sp.

<400> 12
 Met Lys Asn Thr Ile Ser Cys Leu Thr Leu Ala Leu Leu Ser Ala Ser
 1 5 10 15

30 Gln Leu His Ala Gln Thr Ala Ala Asp Ser Ala Tyr Val Arg Asp His
 20 25 30

35 Tyr Glu Lys Thr Glu Val Ala Ile Pro Met Arg Asp Gly Lys Lys Leu
 35 40 45

Phe Thr Ala Ile Tyr Ser Pro Lys Asp Lys Ser Lys Lys Tyr Pro Val
 50 55 60

	Leu	Leu	Asn	Arg	Thr	Pro	Tyr	Thr	Val	Ser	Pro	Tyr	Gly	Gln	Asn	Glu	
	65					70					75					80	
5	Tyr	Lys	Lys	Ser	Leu	Gly	Asn	Phe	Pro	Gln	Met	Met	Arg	Glu	Gly	Tyr	
					85					90					95		
	Ile	Phe	Val	Tyr	Gln	Asp	Val	Arg	Gly	Lys	Trp	Met	Ser	Glu	Gly	Asp	
					100				105					110			
10	Phe	Glu	Asp	Ile	Arg	Pro	Thr	Thr	Tyr	Ser	Lys	Asp	Lys	Lys	Ala	Ile	
					115				120					125			
	Asp	Glu	Ser	Thr	Asp	Thr	Tyr	Asp	Ala	Leu	Glu	Trp	Leu	Gln	Lys	Asn	
					130				135					140			
15	Leu	Lys	Asn	Tyr	Asn	Gly	Lys	Ala	Gly	Leu	Tyr	Gly	Ile	Ser	Tyr	Pro	
	145					150					155					160	
	Gly	Phe	Tyr	Ser	Thr	Val	Gly	Leu	Val	Lys	Thr	His	Pro	Ser	Leu	Lys	
20					165					170					175		
	Ala	Val	Ser	Pro	Gln	Ala	Pro	Val	Thr	Asp	Trp	Tyr	Ile	Gly	Asp	Asp	
					180					185					190		
25	Phe	His	His	Asn	Gly	Val	Leu	Phe	Leu	Gln	Asp	Ala	Phe	Thr	Phe	Met	
					195					200					205		
	Ser	Thr	Phe	Gly	Val	Pro	Arg	Pro	Lys	Pro	Ile	Thr	Pro	Asp	Gln	Phe	
					210					215					220		
30	Lys	Gly	Lys	Ile	Gln	Ile	Lys	Glu	Ala	Asp	Lys	Tyr	Asn	Phe	Phe	Ala	
	225					230					235					240	
	Glu	Ala	Gly	Thr	Ala	Arg	Glu	Leu	Lys	Glu	Lys	Tyr	Phe	Gly	Asp	Ser	
35					245					250					255		
	Val	Gln	Phe	Trp	Asn	Asp	Leu	Phe	Lys	His	Pro	Asp	Tyr	Asp	Asp	Phe	
					260					265					270		

	Trp Lys Ser Arg Val Ile Thr Asn Ser Leu Gln Glu Val Lys Pro Ala	
	275	280 285
5	Val Met Val Val Gly Gly Phe Phe Asp Ala Glu Asp Ala Tyr Gly Thr	
	290	295 300
	Phe Lys Thr Tyr Gln Ser Ile Glu Asp Lys Ser Lys Lys Asn Asn Ser	
	305	310 315 320
10	Ile Leu Val Ala Gly Pro Trp Tyr His Gly Gly Trp Val Arg Ala Glu	
	325	330 335
	Gly Asn Tyr Leu Gly Asp Ile Gln Phe Glu Lys Lys Thr Ser Ile Thr	
15	340	345 350
	Tyr Gln Glu Gln Phe Glu Gln Pro Phe Phe Lys Tyr Tyr Leu Lys Asp	
	355	360 365
	Glu Gly Asn Phe Ala Pro Ser Glu Ala Asn Ile Phe Val Ser Gly Ser	
20	370	375 380
	Asn Glu Trp Lys His Phe Glu Gln Trp Pro Pro Lys Asn Val Glu Thr	
	385	390 395 400
25	Lys Lys Leu Tyr Phe Gln Pro Gln Gly Lys Leu Gly Phe Asp Lys Val	
	405	410 415
	Gln Arg Thr Asp Ser Trp Asp Glu Tyr Val Thr Asp Pro Asn Lys Pro	
30	420	425 430
	Val Pro His Gln Gly Gly Val Ile Gln Asn Arg Thr Arg Glu Tyr Met	
	435	440 445
	Val Asp Asp Gln Arg Phe Ala Ala Ser Arg Pro Asp Val Met Val Tyr	
35	450	455 460
	Gln Thr Glu Pro Leu Thr Glu Asp Leu Thr Ile Val Gly Pro Ile Lys	
	465	470 475 480

	Asn Phe Leu Lys Val Ser Ser Thr Gly Thr Asp Ala Asp Tyr Val Val	
	485	490 495
5	Lys Leu Ile Asp Val Tyr Pro Asn Asp Ala Ala Ser Tyr Gln Gly Lys	
	500	505 510
	Thr Met Ala Gly Tyr Gln Met Met Val Arg Gly Glu Ile Met Ala Gly	
	515	520 525
10	Lys Tyr Arg Asn Gly Phe Asp Lys Ala Gln Ala Leu Thr Pro Gly Met	
	530	535 540
	Val Glu Lys Val Asn Phe Glu Met Pro Asp Val Ala His Thr Phe Lys	
	545	550 555 560
15	Lys Gly His Arg Ile Met Val Gln Val Gln Asn Ser Trp Phe Pro Leu	
	565	570 575
	Ala Glu Arg Asn Pro Gln Val Phe Leu Ala Pro Tyr Thr Ala Thr Lys	
20	580	585 590
	Ala Asp Phe Arg Lys Ala Thr Gln Arg Ile Phe His Asp Val Asn Asn	
	595	600 605
25	Ala Thr Tyr Ile Glu Phe Ser Val Leu Lys Asp	
	610	615
30	<210> 13	
	<211> 30	
	<212> DNA	
	<213> Artificial Sequence	
35	<220>	
	<223> Description of Artificial Sequence:synthesized	
	primer for preparation of pTrpT_Sm_aet	
	<400> 13	

gggaattcca tatgaaaaat acaatttcgt

30

<210> 14

5 <211> 29

<212> DNA

<213> Artificial Sequence

<220>

10 <223> Description of Artificial Sequence:synthesized
primer for preparation of pTrpT_Sm_aet

<400> 14

gctctagact aatctttgag gacagaaaa

29

15

[Brief Description of the Drawings]

[Fig. 1]

Fig. 1 shows the optimum pH of an enzyme of *Empedobacter*.

[Fig. 2]

5 Fig. 2 shows the optimum temperature of an enzyme of
Empedobacter.

[Fig. 3]

Fig. 3 shows the time course of L-alanyl-L-glutamine production from
L-alanine methyl ester and L-glutamine.

10 [Fig. 4]

Fig. 4 shows amounts of an enzyme existing in a cytoplasm fraction
(Cy) and a periplasm fraction (Pe).

[Type of Document] Abstract

[Abstract]

[Object] It is an object of the present invention to provide a method that allows the production of peptides that are equal to or longer than tripeptides


5 easily, inexpensively and at high yield without going through a complex synthesis method.

[Means]

[Selected Figure] None



FIG.1



- ◆ : ACETATE BUFFER(pH 3.9-5.4)
- △ : MES BUFFER(pH5.4~6.4)
- ▲ : PHOSPHATE BUFFER(pH6.0~7.9)
- : BORATE BUFFER(pH7.8~9.3)
- : CAPS BUFFER(pH9.3~10.7)
- : K₂HPO₄-NaOH BUFFER(pH10.8~11.6)

FIG.2





FIG.3



- : L-Ala-L-Gln PRODUCED IN ENZYME - ADDED LOT
- × : RESIDUAL L-Ala-OMe IN ENZYME - ADDED LOT
- ▲ : L-Ala-L-Gln PRODUCED IN ENZYME - NON - ADDED LOT

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.